Document:

Second Amendment of the License Agreement, dated September 25, 2009

 Exhibit 10.2 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been
redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission. 
 SECOND AMENDMENT OF THE LICENSE AGREEMENT 
 The Parties to the License
Agreement of July 10, 2007 (“License Agreement”), SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech
Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and SIGMA-ALDRICH CO., an Illinois corporation having its principal place of business at 3050 Spruce
Street, St. Louis, MO 63103, (“Sigma”), hereby amend the License Agreement (this “Second Amendment”) effective as of September 25, 2009 (the “Amendment Execution Date”) as follows: 
 1. Section 1.70 of the License Agreement shall be amended to read in its entirety as follows: 
 1.70 “Sigma” means Sigma-Aldrich Co., an Illinois corporation. 
 2. Sections 7.3(a)(v) and 7.3(a)(vi) of the License Agreement shall be deleted in their entirety and replaced with the following: 
 (v) $[***] upon delivery by Sangamo to Sigma of: (a) [***] new two-finger modules (archive plate [***] or [***]
as appropriate), which will add a minimum of [***] new hexamers to the archive repertoire. Each module will be characterized by [***] and will specify a minimum of [***] base pairs in its assigned target (using a log odds score based on the [***]
enrichment of the targeted hexamer). The modules will be provided as DNA and glycerol stocks; and (b) a companion set of data files, computer programs and detailed protocols that fully incorporate the new modules into the standard design and
gene assembly process. 
 (vi) $[***] upon delivery by Sangamo to Sigma of: (a) at least [***] new
two-finger modules (archive plate [***] or [***] as appropriate) which will add a minimum of a further [***] new hexamers (separate from those delivered in (vi) above) to the archive repertoire. Each module will be characterized by [***] and
will specify a minimum of [***] base pairs in its assigned target (using a log odds score based on the [***] enrichment of the targeted hexamer). Modules will be provided as DNA and glycerol stocks; and (b) delivery of a companion set of data
files, computer programs and detailed protocols that fully incorporate the new modules into the standard design and gene assembly process. 
 (vii) $[***] upon delivery by Sangamo to Sigma of: (a) a set of new [***] for skipping [***] and [***] with supporting data showing the preference of each new [***] for its intended [***]
length as well as the improved average [***] performance over existing [***]; and (b) delivery of a companion set of data files, computer programs and detailed protocols that fully incorporate the new [***] into the standard design and gene
assembly process. Biochemical studies will consist of [***]. Biological studies will consist of transient ZFN expression in a human cell line followed by Cel-1 analysis for determination of gene modification efficiency of the endogenous targets.

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 1 

 (viii) $[***] upon delivery by Sangamo to Sigma of:
(a) [***]-based design scores for the entire current archive (the two-finger modules on archive plates [***] through [***]); and (b) a companion set of data files, computer programs and detailed protocols that fully incorporate the new
data into the standard design and gene assembly process. Note that modules yielding poor [***] data in these studies may be functionally eliminated from the archive. 
 (ix) $[***] upon initial transfer and demonstration of functional implementation at Sigma of electronic [***]
capabilities as demonstrated by generation of an [***] design sheet. The software will incorporate the existing archive and any new modules, single fingers and [***] available at the time of initial transfer that have been delivered as part of the
work performed above in sections (v), (vi), (vii), and (viii). After initial transfer, the software will be updated as necessary to incorporate platform improvements delivered as part of the work performed above in sections (v), (vi), (vii), and
(viii). 
 (x) $[***] upon delivery by Sangamo to Sigma of data resulting from [***] for [***] new
hexamers focused on the [***]. Data will be comprised of sequencing results from [***] pools. Where sequence data indicate a successful [***] (i.e. via consensus behavior) Sangamo shall follow-up by performing downstream steps of the repertoire
expansion process (generation of module constructs and [***] analysis). Downstream steps will be performed for either [***] modules per successful [***], or [***] modules, whichever value is less. Modules identified via [***] as specific for new
hexamers will then be added to the archive, with supply of such constructs as DNA and glycerol stocks and a companion set of data files, computer programs and detailed protocols that fully incorporate the new modules into the standard design and
gene assembly process. 
 3. Section 7.3(d) of the License Agreement shall be amended in its entirety to read as follows: 
 (d) Sigma shall pay the indicated amounts within thirty (30) days of achievement of the milestone. For clarity, in the event that
Sangamo achieves the milestone described in Section 7.3(a)(iii), Sangamo shall be deemed to have achieved the milestone set forth in Section 7.3(a)(i) (if not previously achieved). For further clarity, achievement of the milestone
described in Section 7.3(a)(iv) shall trigger the milestone payment set forth in Section 7.3(a)(ii) (if not previously paid). 
 4.
Section 13.8 of the License Agreement shall be amended to read in its entirety as follows: 
 13.8 Notices. Any notice
required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently given for all purposes if mailed by first class certified or registered mail,
postage prepaid, express delivery service or personally delivered. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. 
  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 2 

			
	For Sangamo:	  	Sangamo BioSciences, Inc.
		  	Point Richmond Tech Center
		  	501 Canal Boulevard, Suite A100
		  	Richmond, California 94804
		  	Attention: Chief Executive Officer
		
	With a copy to:	  	Cooley Godward Kronish LLP
		  	Five Palo Alto Square
		  	3000 El Camino Real
		  	Palo Alto, CA 94306
		  	Attention: Marya A. Postner, Esq.
		
	For Sigma:	  	Sigma-Aldrich Co.
		  	3050 Spruce Street
		  	St. Louis, Missouri 63103
		  	Attention: General Counsel and Secretary
		
	With a copy to:	  	Sigma-Aldrich Co.
		  	3050 Spruce Street
		  	St. Louis, Missouri 63103
		  	Attention: President, Research Biotech Unit

 5. This Second Amendment amends the terms of the License Agreement and is deemed incorporated into
the License Agreement. The provisions of the License Agreement, as amended by this Second Amendment, remain in full force and effect. 
 6. The
License Agreement as amended by this Second Amendment sets forth the entire understanding of the parties hereto relating to the subject matter thereof and supersedes all prior agreements and understandings among or between any of the parties hereto
relating to the subject matter thereof. 
 7. This Second Amendment may be executed in several counterparts, each of which shall constitute an
original and all of which, when taken together, shall constitute one agreement. The exchange of a fully executed Second Amendment (in counterparts or otherwise) by electronic transmission, including by email, or facsimile shall be sufficient to bind
the Parties to the terms and conditions of this Second Amendment. 
 IN WITNESS
WHEREOF, the Parties have executed this Second Amendment of the License Agreement in duplicate originals by their proper officers as of the Amendment Execution Date. 
  

									
	 SANGAMO BIOSCIENCES, INC.
	 		 	SIGMA-ALDRICH CO.
					
	By:	 	 /s/    Philip D. Gregory
	 		 	By:	 	 /s/    David Smoller

	Name:	 	 Philip D. Gregory
	 		 	Name:	 	 David Smoller

	Title:	 	 Chief Scientific Officer
	 		 	Title:	 	 President

  

 3Third Amendment to the License Agreement, dated October 2, 2009

 Exhibit 10.3 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been
redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission. 
 THIRD AMENDMENT TO THE LICENSE AGREEMENT 
 This THIRD AMENDMENT TO THE LICENSE
AGREEMENT (the “Third Amendment”) is made and entered into as of October 2, 2009 (the “Third Amendment Effective Date”) by and between SANGAMO
BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804
(“Sangamo”), and SIGMA-ALDRICH CO., an Illinois corporation having its principal place of business at 3050 Spruce Street, St. Louis, MO 63103 (“Sigma”). Sigma and
Sangamo are individually referred to herein as a “Party” or collectively as the “Parties”. 
 RECITALS 
 A. Sigma and Sangamo are parties to a License Agreement
effective as of July 10, 2007 as previously amended on November 9, 2007 and September 25, 2009 (the “Agreement”), under which Sangamo granted to Sigma an exclusive license to use Sangamo’s proprietary zinc finger
protein technology in the research field. 
 B. Sigma and Sangamo desire to amend the Agreement in accordance with
Section 13.4 of the Agreement to add a new exclusive license from Sangamo to Sigma for certain commercial uses of products arising from Sangamo’s proprietary zinc finger technology and as otherwise set out herein.  
 NOW, THEREFORE, the Parties agree as follows: 
 1. THIRD AMENDMENT OF THE AGREEMENT 
 The parties hereby agree to amend the terms of the Agreement as provided below, effective as of the Third Amendment Effective Date. Where the
Agreement is not explicitly amended, the terms of the Agreement will remain in force. Capitalized terms used in this Third Amendment that are not otherwise defined herein shall have the same meanings as such terms are given in the Agreement.

 1.1 Section 1.8 shall be amended to read in its entirety as follows: 
 “1.8 [Intentionally deleted]” 
 1.2 Section 1.24 shall be amended to read in its entirety as follows: 
 “1.24 [Intentionally deleted]” 
  

 1. 

 1.3 Section 1.45 shall be amended to read in its entirety as follows:

 “1.45 “Net Sales” means the amount invoiced or otherwise billed by Sigma or its
Sublicensees for sales or other commercial disposition of a Licensed Product in the Field to a Third Party purchaser, less the following to the extent included in such billing or otherwise actually allowed or incurred with respect to such sales:
(a) discounts, including cash, trade and quantity discounts, price reduction programs, retroactive price adjustments with respect to sales of a product, charge-back payments and rebates granted to trade customers; (b) credits or allowances
actually granted upon rejections or returns of Licensed Products, including for recalls or damaged goods; (c) freight, postage, shipping and insurance charges actually allowed or paid for delivery of Licensed Products, to the extent billed;
(d) customs duties, surcharges and other governmental charges incurred in connection with the exportation or importation of a Licensed Product; (e) taxes, duties or other governmental charges levied on, absorbed or otherwise imposed on
sale of Licensed Products, including without limitation value-added taxes, or other governmental charges otherwise measured by the billing amount, when included in billing, as adjusted for rebates and refunds, but specifically excluding taxes based
on net income of the seller; and (f) a reasonable allowance for bad debts (such allowance not to exceed 2% of gross sales) provided that all of the foregoing deductions are calculated in accordance with generally accepted accounting principles
consistently applied throughout the selling party’s organization.” 
 1.4 Section 1.61 shall be amended to
read in its entirety as follows: 
 “1.61 [Intentionally deleted]” 
 1.5 Section 1.66 shall be amended to read in its entirety as follows: 
 “1.66 “Sangamo Know-How” means all Information including Sangamo Improvements and Sangamo’s
interest in Joint Improvements (other than Sangamo Patents), that (a) is Controlled, during the term of this Agreement, by (i) Sangamo, (ii) any entity that, as of the Effective Date or the Third Amendment Effective Date, is a Sangamo
Affiliate, or (iii) a Sangamo Downstream Affiliate and (b) is reasonably necessary or useful to make, use or sell ZFP Products in the Field or the Commercial Field. Sangamo Know-How shall not include any Information licensed to Sangamo or
a Sangamo Affiliate by a Third Party unless such Information is licensed pursuant to a Third Party License and meets the aforementioned criteria for Sangamo Know-How.” 
 1.6 Section 1.67 shall be amended to read in its entirety as follows: 
 “1.67 “Sangamo Patent” means any patent or patent application, including any patent or patent
application that claims a Sangamo Improvement or Joint Improvement, that (a) is Controlled, during the term of this Agreement, by (i) Sangamo, (ii) any entity that, as of the Effective Date or the Third Amendment Effective Date, is a
Sangamo Affiliate, or (iii) a Sangamo Downstream Affiliate, and (b) claims the composition of matter, manufacture, or use of ZFP Products useful in the Field or the Commercial Field. Sangamo Patents include, without limitation, the patents
or patent applications listed on Exhibit A. Notwithstanding the foregoing, Sangamo Patents shall not include any patents or patent applications licensed to Sangamo or a Sangamo Affiliate by a Third Party unless such patents or patent application are
licensed pursuant to a Third Party License.” 
  

 2. 

 1.7 Section 1.75 shall be amended to read in its entirety as follows:

 “1.75 [Intentionally deleted]” 
 1.8 Section 1.78 shall be amended to read in its entirety as follows: 
 “1.78 “Sublicensing Revenues” means any consideration (other than royalties on sales) that Sigma
receives in return for the granting or practice of a sublicense under the Sangamo Technology pursuant to a Sublicense Agreement in which the sublicense under the Sangamo Technology includes rights in the Field, which may include (without limitation)
upfront license fees, annual license or maintenance payments, milestone payments, credits against Sigma’s future expenses, or reductions in royalties or other payments otherwise owed to the Sublicensee. In the event that Sigma receives non-cash
consideration from a Sublicensee for the granting or practice of a sublicense under the Sangamo Technology in the Field, the Parties shall determine in good faith the fair market value of such consideration, and such fair market value shall be
included in Sublicensing Revenues.” 
 1.9 The following new Section 1.93 shall be added to read in its
entirety as follows: 
 “1.93 “Commercial Field” means (a) with respect to a Domestic
Product, the Domestic Field; (b) with respect to a GMP Product or Manufacturing Product, the GMP Field; and (c) with respect to a Livestock Product, the Livestock Field. For clarity, the term “Commercial Field” shall always refer
to the use of a Commercial Product in its applicable field as set forth in the preceding sentence.” 
 1.10 The
following new Section 1.94 shall be added to read in its entirety as follows: 
 “1.94
“Commercial Product” means (a) a Domestic Product, GMP Product, Livestock Product or Manufacturing Product or (b) a Licensed Service that uses in the Commercial Field one of the Licensed Products listed in (a).”

 1.11 The following new Section 1.95 shall be added to read in its entirety as follows: 
 “1.95 “Domestic Field” means the use of a Domestic Product as a companion for humans.” 

 

 3. 

 1.12 The following new Section 1.96 shall be added to read in its entirety as
follows: 
 “1.96 “Domestic Product” means a Licensed Product that is a non-human animal
that is kept as a pet, the genome or genetic composition of which has been modified through the use (whether directly or indirectly) of a ZFP Product.” 
 1.13 The following new Section 1.97 shall be added to read in its entirety as follows: 
 “1.97 “GMP Field” means use for GMP production of Therapeutic Products, including the development of methods for such GMP production. For clarity, if the Therapeutic Product or any
derivative of such Therapeutic Product is used in or administered to humans or animals, then the production of such Therapeutic Product shall be deemed to be GMP production.” 
 1.14 The following new Section 1.98 shall be added to read in its entirety as follows: 
 “1.98 “GMP Product” means a Licensed Product that (a) is a eukaryotic cell or eukaryotic cell
line, the genome or genetic composition of which has been modified through the use (whether directly or indirectly) of a ZFP Product in a manner that (i) facilitates or improves the ability of such cell or cell line to produce a Therapeutic
Product or (ii) modifies the molecular characteristics of such Therapeutic Product and (b) is not a Plant Product.” 
 1.15 The following new Section 1.99 shall be added to read in its entirety as follows: 
 “1.99 “Livestock Field” means use of a Livestock Product for the production of human food or another naturally occurring product.” 
 1.16 The following new Section 1.100 shall be added to read in its entirety as follows: 
 “1.100 “Livestock Product” means a Licensed Product that is a livestock animal (including, but not limited to fish), the genome or genetic composition of which has been modified
through the use (whether directly or indirectly) of a ZFP Product in a manner that improves the quality, quantity or characteristics of a human or animal food or other naturally occurring products (e.g., wool, leather) made by or derived from such
animal, provided that such food or naturally occurring product is not a Therapeutic Product or a ZFP Therapeutic Product.” 
 1.17 The following new Section 1.101 shall be added to read in its entirety as follows: 
 “1.101 “Manufacturing Product” means a Licensed Product that (a) is a multicellular non-human animal, the genome or genetic composition of which has been modified through the use (whether directly or indirectly)
of a ZFP Product in a manner that (i) facilitates or improves the ability of such animal to produce a Therapeutic Product or (ii) modifies the molecular characteristics of such Therapeutic Product and (b) is not a Plant Product.”

  

 4. 

 1.18 The following new Section 1.102 shall be added to read in its entirety as
follows: 
 “1.102 “Net Commercial Sales” means the amount invoiced or otherwise billed by
Sigma for sales or other commercial disposition of a Commercial Product in the Commercial Field to a Third Party purchaser, less the following to the extent included in such billing or otherwise actually allowed or incurred with respect to such
sales: (i) discounts, including cash, trade and quantity discounts, price reduction programs, retroactive price adjustments with respect to sales of a product, charge-back payments and rebates granted to trade customers; (ii) credits or
allowances actually granted upon rejections or returns of Commercial Products, including for recalls or damaged goods; (iii) freight, postage, shipping and insurance charges actually allowed or paid for delivery of Commercial Products, to the
extent billed; (iv) customs duties, surcharges and other governmental charges incurred in connection with the exportation or importation of a Commercial Product; (v) taxes, duties or other governmental charges levied on, absorbed or
otherwise imposed on sale of Commercial Products, including without limitation value-added taxes, or other governmental charges otherwise measured by the billing amount, when included in billing, as adjusted for rebates and refunds, but specifically
excluding taxes based on net income of the seller; and (vi) a reasonable allowance for bad debts (such allowance not to exceed 2% of gross sales) provided that all of the foregoing deductions are calculated in accordance with generally accepted
accounting principles consistently applied throughout Sigma’s organization. 
 In the event that Sigma receives non-cash
consideration for sales or other commercial disposition of a Commercial Product in the Commercial Field to a Third Party purchaser, the Parties shall determine in good faith the fair market value of such consideration, and such fair market value
shall be included in Net Commercial Sales. In the event that Sigma receives a payment attributable to the sale of a Commercial Product that pertains to both the Field and the Commercial Field, then the Parties shall determine in good faith the
relative value of the Field and Commercial Field rights and shall allocate, based upon such relative value, (1) to Net Commercial Sales, the percentage of such payment that corresponds to the percentage value of the rights with respect to the
Commercial Field and (2) to Net Sales, the percentage of such payment that corresponds to the percentage value of the rights with respect to the Field.” 
 1.19 The following new Section 1.103 shall be added to read in its entirety as follows: 
 “1.103 “Net Commercial Sublicensing Revenues” means any consideration that Sigma receives in return for the granting or practice of a sublicense under the Sangamo Technology pursuant
to a Sublicense Agreement in which the sublicense under the Sangamo Technology includes rights in a Commercial Field, which may include (without limitation) upfront license fees, annual license or maintenance payments, milestone payments, royalty
payments or other payments based upon sales made or services offered by the Sublicensee, credits against Sigma’s future expenses, or reductions in royalties or other payments otherwise owed to the Sublicensee. 
  

 5. 

 In the event that Sigma receives non-cash consideration from a Sublicensee for the granting
or practice of a sublicense under the Sangamo Technology in a Commercial Field, the Parties shall determine in good faith the fair market value of such consideration, and such fair market value shall be included in Net Commercial Sublicensing
Revenues. In the event that Sigma receives a payment attributable to the grant of rights with respect to a Commercial Product that pertains to both the Field and the Commercial Field, then the Parties shall determine in good faith the relative value
of the Field and Commercial Field rights and shall allocate, based upon such relative value, (1) to Net Commercial Sublicensing Revenues, the percentage of such payment that corresponds to the percentage value of the rights with respect to the
Commercial Field and (2) to Sublicensing Revenues, the percentage of such payment that corresponds to the percentage value of the rights with respect to the Field.” 
 1.20 The following new Section 1.104 shall be added to read in its entirety as follows: 
 “1.104 “Net Revenues” means the aggregate of all Net Commercial Sales and all Net Commercial
Sublicensing Revenues.” 
 1.21 The following new Section 1.105 shall be added to read in its entirety as
follows: 
 “1.105 “Therapeutic Product” means a product [***]. By way of non-limiting
example, Therapeutic Products shall include [***].” 
 1.22 The following new Section 1.106 shall be added to
read in its entirety as follows: 
 “1.106 “ZFP Therapeutic Product” means [***].”

 1.23 The following new Section 2.1(c) shall be added to read in its entirety as follows: 
 “(c) Additional License Grants. 
 (i) Subject to the terms and conditions of this Agreement, Sangamo hereby grants to Sigma, effective as of the Third
Amendment Effective Date, a royalty-bearing, world-wide, exclusive (except as set forth below) license under the Sangamo Technology (with the right to sublicense as provided below) to make, have made, use, sell, offer for sale, and import GMP
Products in the GMP Field, Domestic Products in the Domestic Field, Livestock Products in the Livestock Field, and Manufacturing Products in the GMP Field (but excluding all uses of GMP Products, Domestic Products, Livestock Products, Manufacturing
Products or Sangamo Technology in the Plant Field and excluding all Plant Products). For clarity, with respect to any animal that is a Domestic Product, Livestock Product, Manufacturing Product or any other Licensed Product, all descendents of such
animal shall also be Licensed Products. 
  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 6. 

 (ii) The licenses set forth in Sections 2.1(a) and 2.1(c)(i) do not
include the creation or use of any Modified Animal (1) [***] or (2) wherein the [***] can be made. Sangamo retains all rights to create and use Modified Animals for such purposes, and Sigma hereby covenants that it shall not use or
practice, nor shall it cause or permit any of its sublicensees (including Sublicensees) to use or practice, directly or indirectly, any Sangamo Technology to create or use Modified Animals for such purposes. For the purposes of this
Section 2.1(c)(ii), “Modified Animal” means a multicellular non-human animal, or tissues or organs from such an animal, the genome or genetic composition of which has been modified through the use (whether directly or indirectly) of a
ZFP Product; and “Discovery” means that the [***]. Without limiting the foregoing and for the sole purpose of providing examples of the implementation of the foregoing, the licenses set forth in Section 2.1(c)(i) shall include
use of a Manufacturing Product in the GMP Field to produce (A) a particular therapeutic protein (for example, a fully human monoclonal antibody) which has been genetically introduced into such Manufacturing Product or (B) therapeutic
antibodies that lack certain glycosylation residues on account of genetic modification of a glycosylation pathway (for example, by knocking out the Fut8 gene) in such Manufacturing Product but the licenses set forth in Sections 2.1(a) and 2.1(c)(i)
shall exclude and Sangamo retains all rights with respect to [***]. 
 (iii) The licenses granted
to Sigma pursuant to Section 2.1(c)(i) are exclusive even as to Sangamo, subject to Sections 2.1(c)(iv) and 2.1(c)(v). Such licenses shall be freely sublicensable by Sigma, provided that Sigma complies with Section 2.2. No Sigma
sublicensee shall be permitted to grant further sublicenses without Sangamo’s prior written approval. 
 (iv) Sigma acknowledges that, prior to the Third Amendment Effective Date, Sangamo has granted to Third Parties the right to use certain Commercial Products in the Commercial Field pursuant to the following agreements: License
Agreement between Sangamo and Pfizer Inc. dated December 19, 2008; License Agreement between Sangamo and Open Monoclonal Technology, Inc. dated April 2, 2008; Research and License Agreement between Sangamo and Genentech, Inc. dated
April 27, 2007; Second Research and License Agreement between Sangamo and Genentech, Inc. dated February 25, 2008; and Research and License Agreement by and among Sangamo, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. dated
July 2, 2008. Sangamo’s grant of an exclusive license in Section 2.1(c)(i) is expressly subject to such previously granted rights. Copies of each such agreement have been provided by Sangamo to Sigma in the publicly available,
redacted form that was filed with the United States Securities and Exchange Commission. 
 (v)
Notwithstanding anything to the contrary in this Agreement, Sangamo and its Affiliates shall retain the non-exclusive right to use Sangamo Technology with respect to Commercial Products in the Commercial Field (1) for their own internal use
or for use with respect to products discovered or developed by Sangamo or its Affiliates, either alone or together with a collaborator (including the right to permit such use of Sangamo Technology with respect to such products by Third Parties that
have licensed such products) or (2) to the extent necessary to fulfill obligations under this Agreement or any agreement with a Third Party, as listed in Section 2.1(c)(iv), existing on the Third Amendment Effective Date.” 

 
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 7. 

 1.24 Section 2.2(b)(ii) shall be amended to read in its entirety as follows:

 “(ii) grant to Sangamo a fully paid, world-wide, irrevocable (subject to Section 10.3(f))
license under any such Improvements that is exclusive for uses outside the Field and outside the Commercial Field and is fully sublicensable.” 
 1.25 Section 2.3(b) shall be amended to read in its entirety as follows: 
 “(b) Licenses to Improvements. Subject to the terms and conditions of this Agreement, Sigma hereby grants to Sangamo and its Affiliates (i) a worldwide, fully paid, perpetual, irrevocable
(subject to Section 10.3(f)), exclusive license (with the right to sublicense) to practice the Sigma Improvements and Joint Improvements (and all patents and patent applications claiming the same) for all purposes outside the Field and outside
the Commercial Field; and (ii) a worldwide, fully paid, perpetual, irrevocable (subject to Section 10.3(f)), non-exclusive license to practice the Sigma Improvements and Joint Improvements in the Field (A) for its own internal use to
identify and develop human and animal therapeutics and (B) in Bona Fide Collaborations with Third Parties to identify and develop human and animal therapeutics (including the right to permit the practice of Sigma Improvements in the Field and
the Commercial Field by such Third Parties in such Bona Fide Collaborations).” 
 1.26 Section 2.4(a) shall be
amended to read in its entirety as follows: 
 “(a) the exclusive right to use, develop, manufacture,
and commercialize (and to grant licenses to use, develop, manufacture, and commercialize) the Sangamo Technology and Licensed Products outside the Field and outside the Commercial Field;” 
 1.27 Section 2.4(b) shall be amended to read in its entirety as follows: 
 “(b) the non-exclusive right to use Sangamo Technology in the Field or in the Commercial Field for their own
internal use or in Bona Fide Collaborations with Third Parties to identify and develop human and animal therapeutics (including the right to permit the use of Sangamo Technology in the Field and in the Commercial Field by such Third Parties in such
Bona Fide Collaborations); and” 
  

 8. 

 1.28 Section 2.5(b) shall be amended to read in its entirety as follows:

 “(b) Sangamo hereby covenants that it shall not use or practice, nor shall it cause or permit any
of its any sublicensees to use or practice, directly or indirectly, any Sigma Improvement for any purpose other than those expressly permitted by this Agreement or to use or practice, directly or indirectly, or grant a license under, any Sangamo
Know-How, Sangamo Patent, Sangamo Improvement, or Joint Improvement in the Field or the Commercial Field in contravention of any licenses granted to Sigma hereunder. Notwithstanding the foregoing, such covenant shall not apply to any Sigma
Improvement that qualifies for one of the exceptions set forth in Section 9.2.” 
 1.29 The third sentence of
Section 2.6(b) shall be amended to read in its entirety as follows: 
 “During such thirty (30) day period, and
thereafter if Sangamo informs Sigma in writing that it intends to pursue a such a license, Sigma hereby covenants that it shall not itself directly license such intellectual property; provided, however, that Sigma shall be permitted, upon prior
written notice to Sangamo, to pursue a direct license under such intellectual property if Sangamo has not obtained a direct license under such intellectual property that is sublicensable to Sigma in the Field and the Commercial Field within nine
(9) months after the date of Sangamo’s receipt of Sigma’s notification.” 
 1.30 Section 2.6(c)
shall be amended to read in its entirety as follows: 
 “(c) Licenses to any intellectual property
relating to ZFP Products in the Field and Commercial Field (including any patents described in Section 7.8) granted to Sangamo shall be deemed to be a Third Party License to the extent the requirements set forth in Section 2.6(d) and/or
(e) (as applicable) are satisfied.” 
 1.31 Section 2.6(d)(i) shall be amended to read in its entirety as
follow: 
 “(i) such Information is reasonably necessary or useful to practice the Sangamo Patents or
to make, use or sell ZFP Products in the Field and the Commercial Field, and Sangamo’s license thereto includes the Field;” 
 1.32 Section 2.6(e)(i) shall be amended to read in its entirety as follow: 
 “(i)
such patent or patent application claims the composition of matter, manufacture, or use of ZFP Products useful in the Field and the Commercial Field, and Sangamo’s license thereto includes the Field;” 
  

 9. 

 1.33 The first and second sentences of Section 2.8 shall be amended to read in
their entirety as follows: 
 “In the event that (a) an entity becomes an Affiliate of Sangamo after the Third
Amendment Effective Date, (b) Sangamo controls (as such term is defined in Section 1.2) such entity, and (c) such entity Controls Information, patents, or patent applications that would satisfy the definition of Sangamo Know-How or
Sangamo Patents (as the case may be) if such entity had been an Affiliate of Sangamo as of the Third Amendment Effective Date, then Sangamo shall provide Sigma with written notice describing such Information, patents, or patent applications in
reasonable detail. If, within thirty (30) days thereafter, Sigma provides written notice to Sangamo that Sigma would like to discuss the economic terms under which such Information, patents, or patent applications would be included in the
Sangamo Technology licensed under this Agreement, the Parties shall negotiate such economic terms in good faith, taking into account the aggregate cost to Sangamo of acquiring control (as such term is defined in Section 1.2) of such entity and
the value of such Information, patents, or patent applications in the Field and Commercial Field relative to the total value of the assets of such entity.” 
 1.34 The first sentence of Section 5.1 shall be replaced by the following two sentences which read in their entirety as follows: 
 “Subject to the terms and conditions of this Agreement, Sigma shall have sole control over, and responsibility for, the development and
commercialization of any Licensed Products in the Field, including the performance of Licensed Services in the Field for Third Parties, and Commercial Products in the Commercial Field, all of which shall be carried out at Sigma’s sole expense.
Sangamo shall promptly refer all further prospective customer inquiries and projects in the Commercial Field to Sigma including all such inquiries and projects under negotiation as of the Third Amendment Effective Date.” 
 1.35 Section 5.2 shall be amended to read in its entirety as follows: 
 “5.2 Diligence. Sigma shall use Diligent Efforts to develop and commercialize Licensed Products in the Field and
Commercial Products in the Commercial Field.” 
 1.36 Section 5.3(a) shall be amended to read in its entirety
as follows: 
 “(a) Sigma shall keep the JSC informed regarding the overall progress and results of
the development and commercialization of any Licensed Products in the Field and Commercial Products in the Commercial Field, in each case by Sigma, its Affiliates, or its Sublicensees, including any written reports requested by the JSC. After the
JSC ceases to exist pursuant to Section 3.1, Sigma shall thereafter provide directly to Sangamo summaries of the development and commercialization activities performed or anticipated to be performed by Sigma, its Affiliates, or its Sublicensees
with respect to Licensed Products in the Field and Commercial Products in the Commercial Field, which summaries shall be in a format and at a frequency decided by the JSC (i.e., prior to the time it ceases to exist) or mutually agreed by the
Parties.” 
  

 10. 

 1.37 Section 5.4 shall be amended to read in its entirety as follows:

 “5.4 “Product Licenses. Any sales of Licensed Products by Sigma under this
Agreement to a Third Party (each, a “Customer”) shall be made pursuant to a written limited use label license (a “Use License”) approved by the JSC. Sigma agrees to label Licensed Products to reflect the terms of
the Use License in a manner reasonably consistent with similar labeled products sold by Sigma. Sigma shall not be obligated to independently verify or confirm that its Customers are or will be in compliance with such Use License, or otherwise
independently verify or confirm that a Customer’s use of Licensed Products falls within the scope of the Field or the Commercial Field, as applicable. For clarity, nothing in the foregoing sentence shall be interpreted to grant Sigma or its
sublicensees any rights under the Sangamo Technology outside the Field or the Commercial Field or to limit Sigma’s obligations under Section 2.5(a). If Sangamo brings to Sigma’s attention a Customer’s use outside the Field or the
Commercial Field, as applicable, of a Licensed Product sold by Sigma, Sigma and Sangamo shall work together in good faith to address such use. The Parties acknowledge and agree that a Use License for sales of Licensed Products in the Field was
approved by the JSC prior to the Third Amendment Effective Date. Promptly after the Third Amendment Effective Date, Sigma shall prepare and present to the JSC for its review, one or more draft Use Licenses for sales of Commercial Products in the
Commercial Field.” 
 1.38 Section 7.9 shall be amended to read in its entirety as follows: 
 “7.9 [Intentionally deleted]” 
 1.39 The first sentence of Section 7.10(a) shall be amended to read in its entirety as follows: 
 “Sangamo (and not Sigma) shall be responsible for paying all fees, milestones, royalties and other compensation owed to Third Parties pursuant to Third Party Licenses identified in Exhibit B as of
the Effective Date or the Third Amendment Effective Date (including any post-Effective Date or post-Third Amendment Effective Date amendments of such Third Party Licenses) on account of (i) the grant to Sigma of the licenses set forth in
Section 2.1 or (ii) the generation, development and/or commercialization of Licensed Products by Sigma, but excluding any payments for which Sigma is responsible pursuant to Section 7.10(b).” 
 1.40 The first sentence of Section 7.10(b) shall be amended to read in its entirety as follows: 
 “Sigma shall be responsible for paying (i) any sublicense issuance and sublicense maintenance fees owed to Third Parties pursuant
to Third Party Licenses on account of the grant of a sublicense by Sigma or its sublicensees and (ii) all milestones, royalties and other compensation owed to Third Parties pursuant to post-Effective Date Third Party Licenses on account of
(A) the grant to Sigma of the licenses set forth in Section 2.1(a) or (B) the generation, development and/or

  

 11. 

 
commercialization of Licensed Products by Sigma, its Affiliates, and Sublicensees within the Field. Sigma shall be responsible for paying (i) any sublicense issuance and sublicense
maintenance fees owed to Third Parties pursuant to Third Party Licenses on account of the grant of a sublicense by Sigma or its sublicensees and (ii) all milestones, royalties and other compensation owed to Third Parties pursuant to post-Third
Amendment Effective Date Third Party Licenses on account of (A) the grant to Sigma of the licenses set forth in Section 2.1(c) or (B) the generation, development and/or commercialization of Commercial Products by Sigma, its
Affiliates, and Sublicensees within the Commercial Field.” 
 1.41 The first sentence of Section 7.10(c) shall
be amended to read in its entirety as follows: 
 “Sigma and Sangamo shall reasonably allocate responsibility for paying
upfront fees or license maintenance fees (i.e., fees paid in consideration for the continued license from the applicable Third Party licensor to Sangamo) owed to Third Parties pursuant to post-Effective Date or post-Third Amendment Effective Date
Third Party Licenses.” 
 1.42 The first sentence of Section 7.14 shall be amended to read in its entirety as
follows: 
 “Each Party shall keep complete, true and accurate books of account and records for the purpose of determining
the payments to be made or received under this Agreement, including without limitation records of Net Sales necessary to verify payments made under Section 7.7 and records of Net Commercial Sales, Net Commercial Sublicensing Revenues and Net
Revenues necessary to verify payments made under Sections 7.19, 7.20 and 7.21, respectively.” 
 1.43
Section 7.16 shall be amended to read in its entirety as follows: 
 “7.16 Additional
Provisions. For the avoidance of doubt, and subject to Section 10.4(c), Sigma shall not be obligated to make any payment pursuant to this Agreement following the termination of this Agreement, except for amounts payable under Sections 7.2,
7.3, 7.4, 7.5, 7.6, 7.7, 7.19, 7.20 and 7.21 which have fully accrued prior to such termination; termination shall not give rise to prorating of any such payment that is not fully accrued at the time of termination. For clarity, any payments payable
under Section 6.2(a) shall be fully accrued upon delivery of the applicable Custom Project Deliverable; any payments due under Section 6.3 shall be fully accrued upon Sangamo incurring the applicable reimbursable costs or expenses; any
payments payable under Section 7.10(b) shall be deemed to have been fully accrued prior to termination to the extent that the triggering event occurred prior to termination and the corresponding payment obligation to the relevant Third Party
licensor comes due prior to, or remains due despite, termination of this Agreement; any milestone payments payable under Section 7.3, 7.4 or 7.21 shall be fully accrued upon achievement of the applicable

  

 12. 

 
milestone event; any payments payable under Section 7.6 shall be fully accrued upon Sigma’s receipt of the applicable Sublicensing Revenue; any royalty payments payable under
Section 7.7 shall be fully accrued on the date of the relevant invoice or other billing giving rise to Net Sales; and any payments payable under Section 7.19 or 7.20 shall be fully accrued upon Sigma’s receipt of the applicable Net
Commercial Sales or Net Commercial Sublicensing Revenue, respectively.” 
 1.44 The following new Section 7.17
shall be added to read in its entirety as follows: 
 “7.17 Commercial License Fee. In consideration
for the licenses to Sangamo Technology set forth in Section 2.1(c), Sigma shall pay Sangamo, within thirty (30) days after the Third Amendment Effective Date, a noncreditable, nonrefundable commercial license fee equal to fifteen million
dollars ($15,000,000). In addition, Sigma shall pay an additional commercial license fee of five million dollars ($5,000,000) as set forth in Sections 7.19(a) and 7.20(a) (the “Additional Commercial License Fee”).” 
 1.45 The following new Section 7.18 shall be added to read in its entirety as follows: 
 “7.18 Additional Equity. Subject to the terms of a separate common stock purchase agreement executed on the Third
Amendment Effective Date (and other agreements and related documents executed pursuant thereto), Sangamo shall issue to Sigma, and Sigma shall purchase, 636,133 shares of Sangamo common stock at a price per share of $7.86.” 
 1.46 The following new Section 7.19 shall be added to read in its entirety as follows: 
 “7.19 Net Commercial Sales-Based Payments. Subject to Section 7.22: 
 (a) Subject to Section 7.22(f), within forty-five (45) days after the end of each calendar quarter up to and
including the Conversion Calendar Quarter, Sigma shall pay Sangamo an Additional Commercial License Fee in an amount equal to [***] percent ([***]%) of the Net Commercial Sales received by Sigma during such calendar quarter; provided, however, that
the aggregate amount paid by Sigma pursuant to this Section 7.19(a) together with Section 7.20(a) shall not exceed five million dollars ($5,000,000). “Conversion Calendar Quarter” shall mean the calendar quarter for which the
payment made by Sigma pursuant to this Section 7.19(a) together with Section 7.20(a) brings the aggregate amount paid by Sigma pursuant to this Section 7.19(a) together with Section 7.20(a) to five million dollars ($5,000,000).

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 13. 

 (b) With respect to those Net Commercial Sales received by Sigma
during the Conversion Calendar Quarter for which no Net Commercial Sales-based payment was owed to Sangamo pursuant to Section 7.19(a) on account of the five million dollar ($5,000,000) limit set forth in Section 7.19(a), Sigma shall pay
Sangamo a royalty in an amount equal to ten and one-half percent (10.5%) of such Net Commercial Sales within forty-five (45) days after the end of the Conversion Calendar Quarter. For example, if the Net Commercial Sales received by Sigma
with respect to a particular calendar quarter equal one million dollars ($1,000,000) and Sigma had already paid Sangamo a total of four million five hundred thousand dollars ($4,500,000) pursuant to Section 7.19(a) together with
Section 7.20(a) with respect to Net Commercial Sales and Net Commercial Sublicensing Revenues received by Sigma in previous calendar quarters, then such calendar quarter shall be the Conversion Calendar Quarter and Sigma shall pay Sangamo [***]
(which is [***]% of $[***]) pursuant to Section 7.19(a) with respect to such calendar quarter and $[***] pursuant to this Section 7.19(b) (which is [***]% of $[***]) with respect to such calendar quarter, in which case all Net Commercial
Sublicensing Revenue payments with respect to such calendar quarter shall be pursuant to Section 7.20(b). 
 (c) Within forty-five (45) days after the end of each calendar quarter after the Conversion Calendar Quarter, Sigma shall pay Sangamo a royalty in an amount equal to ten and one-half percent (10.5%) of the Net Commercial
Sales received by Sigma during such calendar quarter. 
 (d) Each Net Commercial Sales-based payment made
by Sigma to Sangamo pursuant to this Section 7.19 shall be accompanied by a statement that includes sufficient information for Sangamo to understand Sigma’s calculation of such Net Commercial Sales-based payment, including without
limitation an itemization of the amount and type (e.g., sales payments, service fees, etc.) of each payment received by Sigma during the relevant calendar quarter and, with respect to sales payments, identification of the gross sales amount and the
amounts deducted pursuant to Section 1.102(i)-(vi). Each statement shall be deemed to be “Confidential Information” of Sigma. The Net Commercial Sales-based payments made by Sigma to Sangamo pursuant to this Section 7.19 shall be
noncreditable and nonrefundable, except that payments under Section 7.19(a) shall be fully creditable towards the five million dollar ($5,000,000) Additional Commercial License Fee described in Section 7.17, as set forth in
Section 7.19(a).” 
 1.47 The following new Section 7.20 shall be added to read in its entirety as
follows: 
 “7.20 Net Commercial Sublicensing Revenue-Based Payments. 
 (a) Subject to Section 7.22(f), within forty-five (45) days after the end of each calendar quarter up to and
including the Conversion Calendar Quarter, Sigma shall pay Sangamo an Additional Commercial License Fee in an amount equal to [***] percent ([***]%) of the Net Commercial Sublicensing Revenues received by Sigma during such calendar quarter;
provided, however, that the aggregate amount paid by Sigma pursuant to this Section 7.20(a) together with Section 7.19(a) shall not exceed five million dollars ($5,000,000). 
  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 14. 

 (b) With respect to those Net Commercial Sublicensing Revenues
received by Sigma during the Conversion Calendar Quarter for which no Net Commercial Sublicensing Revenue-based payment was owed to Sangamo pursuant to Section 7.20(a) on account of the five million dollar ($5,000,000) limit set forth in
Section 7.20(a), Sigma shall pay Sangamo a royalty in an amount equal to ten and one-half percent (10.5%) of such Net Commercial Sublicensing Revenues within forty-five (45) days after the end of the Conversion Calendar Quarter. For
example, if the Net Commercial Sublicensing Revenues received by Sigma with respect to a particular calendar quarter equal one million dollars ($1,000,000) and Sigma had already paid Sangamo a total of four million five hundred thousand dollars
($4,500,000) pursuant to Section 7.20(a) together with Section 7.19(a) with respect to Net Commercial Sales and Net Commercial Sublicensing Revenues received by Sigma in previous calendar quarters, then such calendar quarter shall be the
Conversion Calendar Quarter and Sigma shall pay Sangamo [***] (which is [***]% of $[***]) pursuant to Section 7.20(a) with respect to such calendar quarter and $[***] pursuant to this Section 7.20(b) (which is [***]% of $[***]) with
respect to such calendar quarter, in which case all Net Commercial Sales payments with respect to such calendar quarter shall be pursuant to Section 7.19(b). 
 (c) Within forty-five (45) days after the end of each calendar quarter after the Conversion Calendar Quarter,
Sigma shall pay Sangamo a royalty in an amount equal to ten and one-half percent (10.5%) of the Net Commercial Sublicensing Revenues received by Sigma during such calendar quarter. 
 (d) Each Net Commercial Sublicensing Revenue-based payment made by Sigma to Sangamo pursuant to this Section 7.20
shall be accompanied by a statement that includes sufficient information for Sangamo to understand Sigma’s calculation of such Net Commercial Sublicensing Revenue-based payment, including without limitation an itemization of the amount and type
(e.g., license fee, milestone payment, etc.) of each payment received by Sigma during the relevant calendar quarter. Each statement shall be deemed to be “Confidential Information” of Sigma. The Net Commercial Sublicensing Revenue-based
payments made by Sigma to Sangamo pursuant to this Section 7.20 shall be noncreditable and nonrefundable, except that payments under Section 7.20(a) shall be fully creditable towards the five million dollar ($5,000,000) Additional
Commercial License Fee described in Section 7.17, as set forth in Section 7.20(a).” 
  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 15. 

	 	1.48 The following new Section 7.21 shall be added to read in its entirety as follows: 

 “7.21 Milestone Payments for Commercial Products. Sigma shall make each of the milestone payments indicated below
to Sangamo within thirty (30) days after aggregate, cumulative Net Revenues of all Commercial Products in the Territory first reach the corresponding dollar values. 
  

			
	 Aggregate, Cumulative Net Revenues of
 Commercial Products (Worldwide)
	 	Payment
		
	 $[***] million
	 	$2 million
		
	 $[***] million
	 	$[***] million
		
	 $[***] million
	 	$[***] million
		
	 $[***] million
	 	$[***] million
		
	 $[***]
	 	$10 million

 The milestone payments made by Sigma to Sangamo pursuant to this Section 7.21
shall be noncreditable and nonrefundable. In no event will the total amount of milestone payments paid by Sigma pursuant to this Section 7.21 exceed twenty-five million dollars ($25,000,000). For the avoidance of doubt, the failure of Sigma to
achieve a level of Net Revenues triggering a payment pursuant to this Section 7.21 shall not be deemed to be a breach of any obligation of Sigma under this Agreement. For clarity, the preceding sentence shall not limit or otherwise affect
Sigma’s obligations pursuant to Section 5.2.” 
 1.49 The following new Section 7.22 shall be added
to read in its entirety as follows: 
 “7.22 Commercial Products. 
 (a) Notwithstanding any other provision of this Agreement to the contrary, sales of Commercial Products and the
performance by Sigma of its rights under Section 2.1(c) shall be subject to the provisions of Sections 7.10 through this Section 7.22 (as such Sections are amended hereby) and shall not be subject to the provisions of Sections 7.1 through
7.9. 
 (b) For clarity, amounts shall be payable pursuant to Section 7.19(c) at the rate set forth
in Section 7.19(c) only with respect to Net Commercial Sales from sales of Commercial Products after the Conversion Calendar Quarter in those countries where the creation, development, manufacture, use or sale of a Commercial Product is covered
by a Valid Claim or where no Third Party is selling a product or service for use in the Commercial Field that competes with such Commercial Product (which competition, for 
  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 16. 

 
clarity, will be assessed on a product-by-product or service-by-service basis and, solely in the case of products, shall require that such product and such Commercial Product involve the
targeting of the same gene (whether or not such targeting is accomplished by the same mechanism)). If that is not the case in a particular country for a particular Commercial Product, then the rate that applies to payments made pursuant to
Section 7.19(c) with respect Net Commercial Sales of such Commercial Product in such country after the Conversion Calendar Quarter shall be five and one-quarter percent (5.25%). 
 (c) Sangamo’s right to receive payments under Section 7.19(c) with respect to a particular country shall
continue, on a Commercial Product-by-Commercial Product basis, for the longer of (i) the expiration of the last to expire Valid Claim in such country covering the creation, manufacture, use or sale of such Licensed Product and (ii) the
15th anniversary of the Third Amendment Effective Date. 
 (d) For the avoidance of doubt, no multiple
payments will be required to be paid under Section 7.19 because a Commercial Product or its manufacture, use, or sale is covered by more than one Valid Claim or patent or patent application within the Sangamo Patents or Sangamo Know-How.

 (e) If there exists in any country during the Term one or more patents of a Third Party that cover ZFP
Products or their use or manufacture and that would be infringed by the making, use or sale of a Commercial Product in the Commercial Field and it is necessary for Sigma or Sangamo to obtain a royalty-bearing license from such Third Party under such
patent(s) in a particular country, then Sigma shall be entitled to a credit, against the payments due to Sangamo pursuant to Sections 7.19 and 7.20 upon sales of such Commercial Product in the applicable country, in an amount equal to fifty percent
(50%) of any royalty paid to such Third Party by Sigma (including royalties paid pursuant to Third Party Licenses) based upon the sales of the Commercial Product in such country, provided that in no event shall the rate of payments due to
Sangamo to be reduced to below 50% of the applicable rates set out in Sections 7.19 and 7.20. 
 (f) If
Net Revenues received by Sigma include non-cash consideration in the form of equity, debt, warrants, convertible debt/equity, a combination thereof or similar equity/debt arrangements, then Sigma may, at its option, make payments under Sections 7.19
and 7.20 by use of a ratable portion of such non-cash consideration. To the extent that Sigma makes any payment under Section 7.19 or 7.20 by use of such non-cash consideration, such non-cash payment to Sangamo shall be calculated using the
percentage set forth in Section 7.19(c) or 7.20(c) (as applicable) (i.e. 10.5%), even if such non-cash payment occurs prior to or during the Conversion Calendar Quarter, and such non-cash payment shall not count towards the five million dollar
($5,000,000) threshold described in Sections 7.19(a) and 7.20(a). For example, if Sigma were to receive stock in exchange for a sublicense grant subject to Section 1.102(c), then Sigma

  

 17. 

 
could use 10.5% of such stock to pay a portion of the amount payable by Sigma under Section 7.19 (subject to the following sentence), and such stock payment shall not count towards the five
million dollar ($5,000,000) threshold described in Section 7.19(a). The determination of whether or not to use such non-cash consideration to make any or all of such payment shall be in Sigma’s sole discretion; provided, however, if Sigma
receives any of the foregoing non-cash consideration in the form of publicly traded securities, Sigma shall be obligated to make the applicable payments due under Section 7.19 and 7.20 with respect to such non-cash consideration in cash, based
on the fair market value of such non-cash consideration. Any transfer of non-cash consideration hereunder shall be subject to all rights and obligations with respect to such non-cash consideration.” 
 1.50 The second sentence of Section 8.5 shall be amended to read in its entirety as follows: 
 “The Parties shall determine on a case-by-case basis, in good faith and by mutual agreement, the allocation of the associated costs and
expenses in connection therewith, which allocation shall take into account the relative value of the applicable Joint Improvement Patent inside and outside the Field and the Commercial Field.” 
 1.51 The first sentence of Section 8.6(a) shall be amended to read in its entirety as follows: 
 “If either Party becomes aware of any Third Party activity in the Field (and outside the Plant Field) or the Commercial Field (and
outside the Plant Field) that infringes a Sangamo Patent or any legal filing made by a Third Party with a court or administrative agency alleging that a Sangamo Patent is invalid or unenforceable (collectively, for the purpose of this
Section 8.6, “Infringement”), then that Party shall give prompt written notice to the other Party regarding such infringement.” 
 1.52 Section 8.7(b) shall be amended to read in its entirety as follows: 
 “(b) With respect to infringement involving Third Party activity outside the Field and the Commercial Field or in the Plant Field, Sangamo shall have the first right, but not the obligation,
to attempt to resolve such infringement, whether by settlement or judgment. If Sangamo fails to resolve such infringement or to initiate a suit with respect thereto within one hundred twenty (120) days after delivery of the notice set forth in
Section 8.7(a), then Sigma shall have the right, but not the obligation, to attempt to resolve such infringement by commercially appropriate steps, including without limitation the filing of an infringement suit using counsel of its own
choice.” 
  

 18. 

 1.53 Section 8.7(c) shall be amended to read in its entirety as follows:

 “(c) With respect to infringement involving Third Party activity solely in the Field or the
Commercial Field (and in each case not in the Plant Field), Sigma shall have the right, but not the obligation, to attempt to resolve such infringement or allegation, whether by settlement or judgment.” 
 1.54 The introductory phrase of Section 8.8(b) shall be amended to read in its entirety as follows: 
 “With respect to infringement of a Joint Improvement Patent involving Third Party activity outside the Field and the Commercial Field or
in the Plant Field:” 
 1.55 The introductory phrase of Section 8.8(c) shall be amended to read in its entirety
as follows: 
 “With respect to infringement of a Joint Improvement Patent involving Third Party activity in the Field or
the Commercial Field (and in each case not in the Plant Field):” 
 1.56 Section 8.9 shall be amended to read
in its entirety as follows: 
 “8.9 Defense of Third Party Infringement Claims. If a Third Party
asserts that a patent or other right Controlled by it is infringed by activities in the Field or the Commercial Field, or a Party becomes aware of a patent or other right that might form the basis for such a claim, the Party first obtaining
knowledge of such a claim or such potential claim shall immediately provide the other Party with notice thereof and the related facts in reasonable detail. The Parties shall discuss the merits of such claim or potential claims and shall attempt, if
they determine doing so to be reasonably appropriate, in good faith to mutually agree whether to obtain a license from such Third Party. If the intellectual property pertains to ZFP Products both inside and outside the Field or the Commercial Field,
then, as between the Parties, Sangamo shall be the party that enters into any license agreement with such Third Party and Sigma shall be entitled to a sublicense in the Field and the Commercial Field under such license agreement (or any license
agreement entered into by Sangamo hereunder that pertains to ZFP Products in the Field or the Commercial Field) if it follows the procedures therefor set forth in Section 2.6(d) and/or 2.6(e) (as applicable). If the intellectual property
pertains to ZFP Product inside but not outside the Field or the Commercial Field, then Section 2.6(b) shall apply. In the event that Sigma is the party that enters into a license agreement with such Third Party, Sigma shall be responsible for
amounts payable with respect to any such license; provided, however, that royalties paid by Sigma pursuant to such license shall be creditable pursuant to Section 7.8 to the extent such royalties satisfy the terms thereof. Neither Party shall
be required to conduct any work under this Agreement which it believes in good faith may infringe Third Party patent or other intellectual property rights. Except as set forth in Article 12 or otherwise agreed in writing by the Parties, each Party
shall control and bear the expense of its own defense of such Third Party claim. The parties shall discuss with each other on a regular basis all actions under and pursuant to this Section 8.9 in order to endeavor in good faith to resolve any
situation hereunder in a manner reasonably satisfactory to both parties.” 
  

 19. 

 1.57 The last three sentences of Section 9.4 shall be amended to read in their
entirety as follows: 
 “In addition, a copy of this Agreement or any amendment thereto may be filed by either Party with
the Securities and Exchange Commission. In connection with any such filing such Party shall endeavor to obtain confidential treatment of economic and trade secret information, and shall keep the other Party informed as the planned filing (including,
but not limited to providing the other Party with the proposed filing reasonably in advance of making the planned filing) and consider the requests of the other Party regarding such confidential treatment. With respect to any Third Party License
that requires Sangamo to provide to the applicable Third Party licensor a copy of this Agreement or any amendment thereto or a summary of the terms of this Agreement or any amendment thereto, Sangamo may provide such copy or summary to such Third
Party licensor in confidence.” 
 1.58 The first sentence of Section 9.7 shall be amended to read in its
entirety as follows: 
 “Subject to Section 9.3, each Party agrees to provide the other Party the opportunity to review
any proposed abstracts, manuscripts or presentations (including verbal presentations) which relate to the use of Licensed Products in the Field or Commercial Field at least thirty (30) days prior to its intended submission for publication (or
in the case of public disclosures by Sigma for the marketing and sales of Licensed Products and Licensed Services, seven (7) days) and agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is
given a reasonable period of time to secure patent protection for any material related to such publication which it believes to be patentable.” 
 1.59 Section 10.2(c) shall be amended to read in its entirety as follows: 
 “(c) Sigma shall grant to Sangamo and its Affiliates a worldwide, fully paid, perpetual, irrevocable, non-exclusive license (with the right to sublicense) to practice the Sigma Improvements
(and any patents and patent applications claiming Sigma Improvements) for all purposes in the Field and the Commercial Field; and” 
 1.60 Section 10.2(d) shall be amended to read in its entirety as follows: 
 “(d) Sigma shall provide Sangamo with a complete and accurate list of (i) all projects in which Sigma, a Sigma Affiliate, or a Sublicensee (to the extent of Sigma’s knowledge)
practiced the Sangamo Technology in the Field or the Commercial Field prior to the termination effective date and (ii) all Licensed Products in existence as of the effective date of termination.” 
  

 20. 

 1.61 Section 10.4(c) shall be amended to read in its entirety as follows:

 “(c) In the event this Agreement is terminated for any reason, Sigma shall cease, and shall cause
its Affiliates and sublicensees to cease, all development and commercialization of Licensed Products, and Sigma shall not use or practice, nor shall it cause or permit any of its Affiliates or such sublicensees to use or practice, directly or
indirectly, any Sangamo Technology; provided, however, that Sigma shall have a six-month period following termination to (i) sell in the Field inventory of Licensed Products existing as of the date of termination and perform in the Field
previously agreed-upon Licensed Services subject to the payment obligations set forth in Section 7.7 (subject to Sections 7.8 through 7.15) and (ii) sell in the Commercial Field inventory of Commercial Products existing as of the date of
termination and perform in the Commercial Field previously agreed-upon services involving use of a Commercial Product in the Commercial Field, in each case subject to the payment obligations set forth in Section 7.19 (subject to Sections 7.10
through 7.15).” 
 1.62 Section 11.3 shall be amended in its entirety as follows: 
 “11.3 Third Party Rights. Except as already disclosed to the other party in writing, each Party represents and
warrants to the other Party that, to its knowledge as of the Effective Date and to its knowledge as of the Third Amendment Effective Date, its performance of work under the Research Plan Collaboration as contemplated by this Agreement will not
infringe the patent, trade secret or other intellectual property rights of any Third Party.” 
 1.63
Section 11.4(a)(ii) shall be amended in its entirety as follows: 
 “(ii) that such Sangamo
Know-How is proprietary to Sangamo, and the conception and development of such Sangamo Know-How by Sangamo has not, to the knowledge of Sangamo as of the Effective Date or as of the Third Amendment Effective Date, constituted or involved the
misappropriation of trade secrets of any Third Party;” 
 1.64 Sections 11.4(b)(ii), (iii), (iv), (v), (vi) and
(vii) shall be amended in their entirety as follows: 
 “(ii) that it is not aware, as of the Effective
Date or as of the Third Amendment Effective Date, of any written assertions of invalidity of those Sangamo Patents that issued prior to the Effective Date or the Third Amendment Effective Date, respectively, other than those disclosed to Sigma in
writing; 
  

 21. 

 (iii) that, as of the Effective Date or as of the Third Amendment Effective
Date, it has not withheld any material references during prosecution in the United States of those United States Sangamo Patents that issued prior to the Effective Date or the Third Amendment Effective Date, respectively; 
 (iv) that the conception, development, and reduction to practice of the inventions claimed in the Sangamo Patents has not, to
the knowledge of Sangamo as of the Effective Date or as of the Third Amendment Effective Date, constituted or involved the misappropriation or infringement of trade secrets or other intellectual property of any Third Party; 
 (v) that, to the knowledge of Sangamo as of the Effective Date or as of the Third Amendment Effective Date, there are no
claims, judgments, or settlements relating to the Sangamo Patents to be paid by Sangamo; 
 (vi) that, to the
knowledge of Sangamo as of the Effective Date or as of the Third Amendment Effective Date, no pending claim has been brought by any person or entity alleging that the Sangamo Patents conflict or interfere with any intellectual property or
proprietary right of any Third Party; and 
 (vii) that Sangamo is not aware, as of the Effective Date or as of
the Third Amendment Effective Date, of any infringement of the Sangamo Patents by a Third Party, other than those disclosed to Sigma in writing.” 
 1.65 The introductory phrase of Section 11.4(c) shall be amended in its entirety as follows: 
 “With respect to the Third Party Licenses set forth in Exhibit B as of the Effective Date and as of the Third Amendment Effective Date, Sangamo represents and warrants with respect to those items
below that pertain to current facts, and covenants with respect to those items below that pertain to future actions:” 
 1.66 Section 11.4(c)(i) shall be amended in its entirety as follows: 
 “(i) that, to
its knowledge as of the Effective Date and as of the Third Amendment Effective Date, it is not in material breach of its obligations thereunder as of the Effective Date and as of the Third Amendment Effective Date, respectively, and it will continue
to perform all of its obligations thereunder that, if not performed, would have a material adverse effect on Sigma’s rights under this Agreement,” 
 1.67 Section 11.4(c)(vi) shall be amended in its entirety as follows: 
 “(vi) that the conception, development, and reduction to practice of the technology licensed in the Field or the Commercial Field under Third Party Licenses is not known by Sangamo as of the
Effective Date or the Third Amendment Effective Date to have constituted or involved the misappropriation or infringement of trade secrets or other intellectual property of any Third Party.” 
  

 22. 

 1.68 Section 11.4(d)(i) shall be amended in its entirety as follows: 

“(i) As of the Effective Date and as of the Third Amendment Effective Date, the only license granted by Sangamo under
the Sangamo Technology to make, use and/or sell products in the Plant Field is the Dow AgroSciences Agreement.” 
 1.69
Section 11.5(a) shall be amended in its entirety as follows: 
 “(a) On written request by
Sigma, Sangamo will discuss in good faith with Sigma an appropriate accommodation (which may involve a reduction in certain future payments owed to Sangamo under this Agreement) to reflect the reduced commercial value of the licenses granted to
Sigma under this Agreement as a result of activity in the Field or Commercial Field by unlicensed Third Parties that has a material adverse effect on Sigma’s ability to exploit its rights under this Agreement.” 
 1.70 Exhibit A of the Agreement shall be deleted and replaced by Exhibit A to this Third Amendment. 
 2. MISCELLANEOUS 
 2.1 Full Force and Effect. This Third Amendment amends the terms of the Agreement and is deemed incorporated into the Agreement. The provisions of the Agreement, as amended by this Third Amendment, remain in full force and effect.

 2.2 Entire Agreement. The Agreement as amended by this Third Amendment sets forth the entire understanding of the
parties hereto relating to the subject matter thereof and supersedes all prior agreements and understandings among or between any of the parties hereto relating to the subject matter thereof. 
 2.3 Counterparts. This Third Amendment may be executed in several counterparts, each of which shall constitute an original and all of
which, when taken together, shall constitute one agreement. The exchange of a fully executed Third Amendment (in counterparts or otherwise) by electronic transmission, including by email, or facsimile shall be sufficient to bind the Parties to the
terms and conditions of this Third Amendment. 
  

 23. 

 IN WITNESS WHEREOF, the
Parties have executed this Third Amendment in duplicate originals by their proper officers as of the Third Amendment Effective Date. 
  

									
	SANGAMO BIOSCIENCES, INC.	 		 	SIGMA-ALDRICH CO.
					
	By:	 	 /s/    H. Ward Wolff
	 		 	By:	 	 /s/    David Smoller

	Name:	 	 H. Ward Wolff
	 		 	Name:	 	 David Smoller

	Title:	 	 EVP & CFO
	 		 	Title:	 	 President RBBV

  

 24. 

 Appendix A 
 (note- bold italic indicates items added since July 2007) 
  

													
	 Reference
 number
	  	 Country
	  	 Patent number
 (publication)
	  	 Title
	  	 Application
 number
	  	 Filing Date
	  	 Status

	 S1
	  	US	  	6453242	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	09/229,007	  	12-Jan-99	  	Issued
							
	 S1
	  	US	  	6785613	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	10/113,424	  	27-Mar-02	  	Issued
							
	 S1
	  	US	  	7177766	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	09/825,242	  	2-Apr-01	  	Issued
							
	 S1
	  	US	  	(2007-0287189)	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	11/707,284	  	12-Feb-07	  	Pending
							
	 S1
	  	PCT	  	WO0042219	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	US00/00388	  	6-Jan-00	  	National Phase
							
	 S1
	  	AU	  	744171	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	27220/00	  	6-Jan-00	  	Issued
							
	 S1
	  	CA	  	(2,322,700)	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	2,322,700	  	6-Jan-00	  	Pending
							
	 S1
	  	EP	  	EP 1 075 540	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	905563.3	  	6-Jan-00	  	Issued
							
	 S1
	  	BE	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	905563.3	  	6-Jan-00	  	Issued
							
	 S1
	  	CH	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	905563.3	  	6-Jan-00	  	Issued

  

 25. 

													
	S1	  	DE	  	600 05 100.5-08	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	905563.3	  	6-Jan-00	  	Issued
							
	S1	  	FR	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	905563.3	  	6-Jan-00	  	Issued
							
	S1	  	IE	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	905563.3	  	6-Jan-00	  	Issued
							
	S1	  	EP	  	EP 1 352 975	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	03 015 798.6	  	6-Jan-00	  	Issued
							
	S1	  	BE	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	03 015 798.6	  	6-Jan-00	  	Issued
							
	S1	  	CH	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	03 015 798.6	  	6-Jan-00	  	Issued
							
	S1	  	DE	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	03 015 798.6	  	6-Jan-00	  	Issued
							
	S1	  	FR	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	03 015 798.6	  	6-Jan-00	  	Issued
							
	S1	  	IE	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	03 015 798.6	  	6-Jan-00	  	Issued
							
	S1	  	GB	  	GB2348425	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	03 015 798.6	  	12-Jan-00	  	Issued
							
	S1	  	GB	  	GB2360285	  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	03 015 798.6	  	9-May-01	  	Issued
							
	S1	  	JP	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	2000-593776	  	6-Jan-00	  	appeal

  

 26. 

													
	S1	  	JP	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	2001-117552	  	6-Jan-00	  	appeal
							
	S1	  	JP	  		  	Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites	  	2008-262287	  	8-Oct-2008	  	pending
							
	S2	  	US	  	7163824	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	10/222,614	  	15-Aug-02	  	Issued
							
	S2	  	US	  	6534261	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	09/229,037	  	12-Jan-99	  	Issued
							
	S2	  	US	  	6607882	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	09/478,681	  	6-Jan-00	  	Issued
							
	S2	  	US	  	6824978	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	09/706,243	  	3-Nov-00	  	Issued
							
	S2	  	US	  	6979539	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	09/897,844	  	2-Jul-01	  	Issued
							
	S2	  	US	  	6933113	  	Modulation of endogenous gene expression in cells	  	09/942,087	  	28-Aug-01	  	Issued
							
	S2	  	US	  	7013219	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	10/245,415	  	16-Sep-02	  	Issued
							
	S2	  	US	  	7220719	  	Modulation of endogenous gene expression in cells	  	10/845,384	  	13-May-04	  	issued
							
	S2	  	US	  	(20050215502)	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	10/984,304	  	9-Nov-04	  	Pending
							
	S2	  	US	  	(20050130304)	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	10/986,583	  	12-Nov-04	  	Pending
							
	S2	  	US	  	(20050239203)	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	11/148,794	  	8-Jun-05	  	Pending
							
	S2	  	US	  	(20060276427)	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	11/505,044	  	16-Aug-06	  	Pending
							
	S2	  	US	  	(20060281704)	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	11/505,775	  	17-Aug-06	  	Pending
							
	S2	  	US	  	NP	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	11/521,291	  	14-Sep-06	  	Pending
							
	S2	  	US	  	NP	  	Alteration of Tumor Growth Using Zinc Finger Proteins	  	11/524,165	  	20-Sep-06	  	Pending
							
	S2	  	PCT	  	WO0041566	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	US00/00409	  	6-Jan-00	  	National Phase

  

 27. 

													
	S2	  	AU	  	745844	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	28470/00	  	6-Jan-00	  	Issued
							
	S2	  	CA	  	2,323,086	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	2323086	  	6-Jan-00	  	issued
							
	S2	  	EP	  	EP 1 061 805	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	AT	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	BE	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	CH	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	CY	  	CY 1104346	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	DE1	  	600 22 705.7-08	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	DE2	  	200 23 745.4	  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	DK	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	ES	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	FI	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	FR	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	GR	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	IE	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	IT	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	LU	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	MC	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued

  

 28. 

													
	S2	  	NL	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	PT	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	SE	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	GB	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	906882.6	  	6-Jan-00	  	Issued
							
	S2	  	JP	  		  	Regulation of endogenous gene expression in cells using zinc finger proteins	  	2001-5820	  	12-Jan-01	  	Pending
							
	S7	  	US	  	6599692	  	Functional genomics using zinc finger proteins	  	09/395,448	  	14-Sep-99	  	Issued
							
	S7	  	US	  	6777185	  	Functional genomics using zinc finger proteins	  	09/925,796	  	9-Aug-01	  	Issued
							
	S7	  	US	  	6780590	  	Gene identification	  	09/941,450	  	28-Aug-01	  	Issued
							
	S7	  	US	  	7235354	  	Functional genomics using zinc finger proteins	  	10/843,944	  	12-May-04	  	Issued
							
	S7	  	US	  	(20050032108)	  	Methods for genome annotation	  	10/922,546	  	19-Aug-04	  	Pending
							
	S7	  	PCT	  	WO0119981	  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	US00/24897	  	12-Sep-00	  	National Phase
							
	S7	  	PCT	  	WO03020887	  	Gene Identification	  	US02/27310	  	27-Aug-02	  	National Phase
							
	S7	  	AU	  	778964	  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	74787/00	  	12-Sep-00	  	Issued
							
	S7	  	CA	  	2,383,926	  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	2383926	  	12-Sep-00	  	Issued
							
	S7	  	EP	  	EP1238067	  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	963362.9	  	12-Sep-00	  	Issued
							
	S7	  	BE	  		  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	963362.9	  	12-Sep-00	  	Issued

  

 29. 

													
	S7	  	CH	  		  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	963362.9	  	12-Sep-00	  	Issued
							
	S7	  	DE	  	600 25 037.7-08	  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	963362.9	  	12-Sep-00	  	Issued
							
	S7	  	FR	  		  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	963362.9	  	12-Sep-00	  	Issued
							
	S7	  	GB	  		  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	963362.9	  	12-Sep-00	  	Issued
							
	S7	  	HK	  		  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	963362.9	  	12-Sep-00	  	Issued
							
	S7	  	IE	  		  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	963362.9	  	12-Sep-00	  	Issued
							
	S7	  	JP	  		  	FUNCTIONAL GENOMICS USING ZINC FINGER PROTEINS	  	2001-523752	  	12-Sep-00	  	Pending
							
	S9	  	US	  	6503717	  	Methods of using randomized libraries of zinc finger proteins for the identification of gene function	  	09/731,558	  	6-Dec-00	  	Issued
							
	S9	  	US	  	7491531	  	Methods of using randomized libraries of zinc finger proteins for the identification of gene function	  	10/337,216	  	6-Jan-03	  	Issued
							
	S9	  	US	  	(20060166263)	  	Randomized libraries of zinc finger proteins	  	11/394,279	  	29-Mar-06	  	Pending
							
	S9	  	US	  	(20060292621)	  	Randomized libraries of zinc finger proteins	  	11/486,254	  	12-Jul-06	  	Pending-
							
	S9	  	PCT	  	WO0140798	  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	US00/33086	  	6-Dec-00	  	National Phase
							
	S9	  	AU	  	776576	  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	24278/01	  	6-Dec-00	  	Issued
							
	S9	  	CA	  	(2,394,850)	  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	2,394,850	  	6-Dec-00	  	Pending

  

 30. 

													
	S9	  	EP	  	EP1236045	  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	988919.6	  	6-Dec-00	  	Issued
							
	S9	  	BE	  		  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	988919.6	  	6-Dec-00	  	Issued
							
	S9	  	CH	  		  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	988919.6	  	6-Dec-00	  	Issued
							
	S9	  	DE	  	600 23 936.5-08	  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	988919.6	  	6-Dec-00	  	Issued
							
	S9	  	FR	  		  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	988919.6	  	6-Dec-00	  	Issued
							
	S9	  	GB	  		  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	988919.6	  	6-Dec-00	  	Issued
							
	S9	  	HK	  	1 049 515	  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	988919.6	  	6-Dec-00	  	Issued
							
	S9	  	IE	  		  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	988919.6	  	6-Dec-00	  	Issued
							
	S9	  	IL	  	150069	  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  		  	6-Dec-00	  	Issued
							
	S9	  	IL	  		  	METHODS OF USING RANDOMIZED LIBRARIES OF ZINC FINGER PROTEINS FOR THE IDENTIFICATION OF GENE FUNCTION	  	187848	  	6-Dec-00	  	Pending
							
	S10	  	US	  	6689558	  	Cells for drug discovery	  	09/779,233	  	8-Feb-01	  	Issued
							
	S10	  	US	  	7045304	  	Cells for drug discovery	  	10/412,109	  	10-Apr-03	  	Issued
							
	S10	  	US	  	6989269	  	Cells for drug discovery	  	10/412,105	  	10-Apr-03	  	Issued
							
	S10	  	PCT	  	WO0159450	  	Cells for drug discovery	  	US01/04301	  	8-Feb-01	  	National Phase
							
	S10	  	AU	  		  	Cells for drug discovery	  	2001 250774	  	8-Feb-01	  	Issued
							
	S10	  	CA	  	(2,398,590)	  	Cells for drug discovery	  	2,398,590	  	8-Feb-01	  	Pending
							
	S10	  	EP	  	(EP1254369)	  	CELLS EXPRESSING ZINC FINGER PROTEIN FOR DRUG DISCOVERY	  	01 924 089.4	  	8-Feb-01	  	Pending

  

 31. 

													
	S10	  	HK	  		  	CELLS EXPRESSING ZINC FINGER PROTEIN FOR DRUG DISCOVERY	  	3103204.3	  		  	Pending
							
	S10	  	JP	  		  	Cells for drug discovery	  	2001-558729	  	8-Feb-01	  	Pending
							
	S10	  	JP	  		  	Cells for drug discovery	  	2002-311841	  	25-Oct-02	  	Pending
							
	S10	  	KR	  		  	Cells for drug discovery	  	2002-7010228	  	8-Feb-01	  	Pending
							
	S11	  	US	  	7030215	  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	09/990,186	  	20-Nov-01	  	Issued
							
	S11	  	US	  	7585849	  	Position dependent recognition of GNN nucleotide triplets by zinc fingers	  	11/202,009	  	11-Aug-05	  	Issued
							
	S11	  	US	  	(2008-0242847)	  	Position dependent recognition of GNN nucleotide triplets by zinc fingers	  	11/893,341	  	15-Aug-07	  	Pending
							
	S11	  	PCT	  	WO0242459	  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	US01/43438	  	20-Nov-01	  	National Phase
							
	S11	  	AU	  	2002 239295	  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	2002 239295	  	20-Nov-01	  	Issued
							
	S11	  	CA	  	(2,429,555)	  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	2,429,555	  	20-Nov-01	  	Pending
							
	S11	  	EP	  	EP 1 364 020	  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	01 987 037.7	  	20-Nov-01	  	Issued
							
	S11	  	BE	  		  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	01 987 037.7	  	20-Nov-01	  	Issued
							
	S11	  	CH	  		  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	01 987 037.7	  	20-Nov-01	  	Issued
							
	S11	  	DE	  		  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	01 987 037.7	  	20-Nov-01	  	Issued
							
	S11	  	FR	  		  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	01 987 037.7	  	20-Nov-01	  	Issued

  

 32. 

													
	S11	  	GB	  		  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	01 987 037.7	  	20-Nov-01	  	Issued
							
	S11	  	IE	  		  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	01 987 037.7	  	20-Nov-01	  	Issued
							
	S11	  	HK	  		  	POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE TRIPLETS BY ZINC FINGERS	  	03102869.1	  	20-Nov-01	  	Issued
							
	S12	  	US	  	(20020064802)	  	METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN	  	09/844,662	  	27-Apr-01	  	Pending-
							
	S12	  	PCT	  	WO0183751	  	METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN	  	US01/13631	  	27-Apr-01	  	National Phase
							
	S12	  	AU	  	2001 255748	  	METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN	  	2001 255748	  	27-Apr-01	  	Issued
							
	S12	  	CA	  	(2,407,695)	  	METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN	  	2,407,695	  	27-Apr-01	  	Pending
							
	S12	  	EP	  	(EP1276865)	  	METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN	  	1928946.1	  	27-Apr-01	  	Pending
							
	S12	  	HK	  		  	METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN	  	3105064.7	  		  	Pending
							
	S12	  	JP	  		  	METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN	  	2001-580358	  	27-Apr-01	  	Pending
							
	S14	  	US	  	7001768	  	Targeted modification of chromatin structure	  	09/844,508	  	27-Apr-01	  	Issued
							
	S14	  	US	  	(20090023153)	  	Targeted modification of chromatin structure	  	12/217,953	  	10-Jul-08	  	Pending
							
	S14	  	PCT	  	WO0183793	  	Targeted modification of chromatin structure	  	US01/40616	  	27-Apr-01	  	National Phase
							
	S14	  	AU	  		  	Targeted modification of chromatin structure	  	2001 253914	  	27-Apr-01	  	Issued
							
	S14	  	CA	  	(2,407,460)	  	Targeted modification of chromatin structure	  	2,407,460	  	27-Apr-01	  	Pending
							
	S14	  	EP	  	EP 1 276 859	  	Targeted modification of chromatin structure	  	01 927 467.9	  	27-Apr-01	  	Issued
							
	S14	  	BE	  		  	Targeted modification of chromatin structure	  	01 927 467.9	  	27-Apr-01	  	Issued

  

 33. 

													
	S14	  	CH	  		  	Targeted modification of chromatin structure	  	01 927 467.9	  	27-Apr-01	  	Issued
							
	S14	  	DE	  		  	Targeted modification of chromatin structure	  	01 927 467.9	  	27-Apr-01	  	Issued
							
	S14	  	FR	  		  	Targeted modification of chromatin structure	  	01 927 467.9	  	27-Apr-01	  	Issued
							
	S14	  	GB	  		  	Targeted modification of chromatin structure	  	01 927 467.9	  	27-Apr-01	  	Issued
							
	S14	  	IE	  		  	Targeted modification of chromatin structure	  	01 927 467.9	  	27-Apr-01	  	Issued
							
	S16	  	US	  	6511808	  	Methods for designing exogenous regulatory molecules	  	09/844,493	  	27-Apr-01	  	Issued
							
	S16	  	PCT	  	WO0183819	  	Methods for designing exogenous regulatory molecules	  	US01/13562	  	27-Apr-01	  	National Phase
							
	S19	  	US	  	6919204	  	MODULATION OF GENE EXPRESSION USING LOCALIZATION DOMAINS	  	09/967,869	  	28-Sep-01	  	Issued
							
	S20	  	US	  	6794136	  	Iterative optimization in the design of binding proteins	  	09/716,637	  	20-Nov-00	  	Issued
							
	S21	  	US	  	(20030232781)	  	Modulation of gene expression using insulator binding proteins	  	10/446,901	  	27-May-03	  	Pending
							
	S21	  	US	  	(20090181455)	  	Modulation of gene expression using insulator binding proteins	  	12/287,409	  	9-Oct-08	  	Pending
							
	S21	  	PCT	  	WO0244376	  	Modulation of gene expression using insulator binding proteins	  	US01/44654	  	28-Nov-01	  	National Phase
							
	S25	  	US	  	(2003-0108880)	  	Modified zinc finger binding proteins	  	10/055,711	  	22-Jan-02	  	Pending
							
	S25	  	US	  	(2006-0246567)	  	Modified zinc finger binding proteins	  	11/486,158	  	13-Jul-06	  	Pending
							
	S25	  	US	  	(2006-0246588)	  	Modified zinc finger binding proteins	  	11/485,946	  	13-Jul-06	  	Pending
							
	S25	  	PCT	  	WO0257293	  	Modified zinc finger binding proteins	  	US02/01893	  	22-Jan-02	  	National Phase
							
	S25	  	AU	  	2002241946	  	Modified zinc finger binding proteins	  	2002 241946	  	22-Jan-02	  	Issued
							
	S25	  	CA	  	(2,435,394)	  	Modified zinc finger binding proteins	  	2,435,394	  	22-Jan-02	  	Pending
							
	S25	  	EP	  	(EP1353941)	  	Modified zinc finger binding proteins	  	02 707 545.6	  	22-Jan-02	  	Pending

  

 34. 

													
	S26	  	US	  	7273923	  	Zinc finger proteins for DNA binding and gene regulation in plants	  	10/055,713	  	22-Jan-02	  	Issued
							
	S26	  	US	  	7262054	  	ZINC FINGER PROTEINS FOR DNA BINDING AND GENE REGULATION IN PLANTS	  	10/470,180	  	22-Jan-02	  	Issued
							
	S26	  	US	  	(20060294617)	  	ZINC FINGER PROTEINS FOR DNA BINDING AND GENE REGULATION IN PLANTS	  	11/511,106	  	28-Aug-06	  	Pending
							
	S26	  	US	  	(20070065931)	  	ZINC FINGER PROTEINS FOR DNA BINDING AND GENE REGULATION IN PLANTS	  	11/583,967	  	19-Oct-06	  	Pending
							
	S26	  	PCT	  	WO0257294	  	ZINC FINGER PROTEINS FOR DNA BINDING AND GENE REGULATION IN PLANTS	  	US02/01906	  	22-Jan-02	  	National Phase
							
	S27	  	PCT	  	WO03027247	  	Modulation of Stem Cells Using Zinc Finger Proteins	  	US02/30413	  	24-Sep-02	  	National Phase
							
	S27	  	AU	  	2002330097	  	Modulation of Stem Cells Using Zinc Finger Proteins	  	2002 330097	  	24-Sep-02	  	Issued
							
	S27	  	CA	  	(2,461,290)	  	Modulation of Stem Cells Using Zinc Finger Proteins	  	2,461,290	  	24-Sep-02	  	Pending
							
	S27	  	EP	  	(EP1435779)	  	Modulation of Stem Cells Using Zinc Finger Proteins	  	02 766 356.6	  	24-Sep-02	  	Pending
							
	S27	  	US	  	(20060251642)	  	Modulation of Stem Cells Using Zinc Finger Proteins	  	10/490,787	  	24-Sep-02	  	Pending
							
	S28	  	US	  	(20030180777)	  	Rapid identification of transcriptional regulatory domains	  	10/387,320	  	11-Mar-03	  	Pending
							
	S30	  	US	  	7070934	  	Ligand-controlled regulation of endogenous gene expression	  	10/456,444	  	5-Jun-03	  	Issued
							
	S32	  	US	  	7361635	  	Simultaneous modulation of multiple genes	  	10/651,761	  	29-Aug-03	  	Issued
							
	S32	  	US	  	(20080233641)	  	Simultaneous modulation of multiple genes	  	12/072,871	  	28-Feb-08	  	Pending
							
	S36	  	US	  	(20050064474)	  	Methods and compositions for targeted cleavage and recombination	  	10/912,932	  	6-Aug-04	  	Pending
							
	S36	  	US	  	(20060188987)	  	Targeted deletion of cellular DNA sequences	  	11/304,981	  	15-Dec-05	  	Pending
							
	S36	  	US	  	(20070218528)	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	10/587,723	  	3-Feb-05	  	Pending

  

 35. 

													
	S36	  	PCT	  	WO2005014791	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	US04/25407	  	6-Aug-04	  	National Phase
							
	S36	  	PCT	  	WO2005084190	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	US05/03245	  	3-Feb-05	  	National Phase
							
	S36	  	AU	  	2004263865	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	2004 263865	  	6-Aug-04	  	Issued
							
	S36	  	AU	  		  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	2007 201649	  		  	Pending
							
	S36	  	CA	  	(2,534,296)	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	2,534,296	  	6-Aug-04	  	Pending
							
	S36	  	EP	  	(EP1651660)	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	04 780 272.3	  	6-Aug-04	  	Pending
							
	S36	  	HK	  		  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	6107666.2	  	7-July-06	  	Pending
							
	S36	  	HK	  	(1094009A)	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	7100975.2	  	26-Jan-07	  	Pending
							
	S36	  	IL	  		  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	173460	  	6-Aug-04	  	Pending
							
	S36	  	JP	  		  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	2006-523239	  	6-Aug-04	  	Pending
							
	S36	  	KR	  		  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	2006-7002703	  	6-Aug-04	  	Pending
							
	S36	  	SG	  	119570	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	2006 00748-8	  	6-Aug-04	  	issued

  

 36. 

													
	S36	  	AU	  		  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	2005 220148	  	3-Feb-05	  	Pending
							
	S36	  	CA	  	(2,554,966)	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	2,554,966	  	3-Feb-05	  	Pending
							
	S36	  	EP	  	(EP1720995)	  	METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION	  	05 756 438.7	  	3-Feb-05	  	Pending
							
	S38	  	US	  	7407776	  	ENGINEERED ZINC FINGER PROTEINS FOR REGULATION OF GENE EXPRESSION	  	10/572,886	  	17-Sep-04	  	Issued
							
	S38	  	PCT	  	WO0528630	  	ENGINEERED ZINC FINGER PROTEINS FOR REGULATION OF GENE EXPRESSION	  	US04/30606	  	17-Sep-04	  	National Phase
							
	S38	  	AU	  	(2004272957)	  	ENGINEERED ZINC FINGER PROTEINS FOR REGULATION OF GENE EXPRESSION	  	2004 274957	  	17-Sep-04	  	Pending
							
	S38	  	CA	  	(2,539,439)	  	ENGINEERED ZINC FINGER PROTEINS FOR REGULATION OF GENE EXPRESSION	  	2,539,439	  	17-Sep-04	  	Pending
							
	S38	  	EP	  	(EP 1678315)	  	ENGINEERED ZINC FINGER PROTEINS FOR REGULATION OF GENE EXPRESSION	  	04 784 464.2	  	17-Sep-04	  	Pending
							
	S43	  	US	  	(2006-0063231)	  	Compositions and methods for protein production	  	11/221,683	  	8-Sep-05	  	Pending
							
	S43	  	PCT	  	WO2006033859	  	Compositions and methods for protein production	  	US05/32157	  	8-Sep-05	  	National Phase
							
	S43	  	AU	  		  	Compositions and methods for protein production	  	2005 287278	  	8-Sep-05	  	Pending
							
	S43	  	CA	  	(2,579,677)	  	Compositions and methods for protein production	  	2,579,677	  	8-Sep-05	  	Pending
							
	S43	  	EP	  	(EP1789095)	  	Compositions and methods for protein production	  	05 794 863.0	  	8-Sep-05	  	Pending
							
	S43	  	IN	  		  	Compositions and methods for protein production	  	1023/KOLNP/2007	  	8-Sep-05	  	Pending
							
	S43	  	KR	  		  	Compositions and methods for protein production	  	10-2007-7008516	  	8-Sep-05	  	Pending
							
	S43	  	SG	  		  	Compositions and methods for protein production	  	200701773-4	  	8-Sep-05	  	Pending

  

 37. 

													
	S43	  	HK	  		  	Compositions and methods for protein production	  	7109703.2	  	8-Sep-05	  	Pending
							
	S46	  	US	  	(20070134796)	  	Targeted integration and expression of exogenous nucleic acid sequences	  	11/493,423	  	26-Jul-06	  	Pending
							
	S46	  	PCT	  	WO2007014275	  	Targeted integration and expression of exogenous nucleic acid sequences	  	US06/029027	  	26-Jul-06	  	National Phase
							
	S46	  	AU	  		  	Targeted integration and expression of exogenous nucleic acid sequences	  	2006272634	  	26-Jul-06	  	Pending
							
	S46	  	CA	  	(2,615,532)	  	Targeted integration and expression of exogenous nucleic acid sequences	  	2,615,532	  	26-Jul-06	  	Pending
							
	S46	  	CN	  		  	Targeted integration and expression of exogenous nucleic acid sequences	  	200680035070.4	  	26-Jul-06	  	Pending
							
	S46	  	EP	  	(EP1913149)	  	Targeted integration and expression of exogenous nucleic acid sequences	  	06 788 559.0	  	26-Jul-06	  	Pending
							
	S46	  	HK	  		  	Targeted integration and expression of exogenous nucleic acid sequences	  	1115064A	  	26-Jul-06	  	Pending
							
	S46	  	IL	  		  	Targeted integration and expression of exogenous nucleic acid sequences	  	188966	  	26-Jul-06	  	Pending
							
	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]
							
	S46	  	KR	  		  	Targeted integration and expression of exogenous nucleic acid sequences	  	10-2008-7004618	  	26-Jul-06	  	Pending
							
	S46	  	SG	  		  	Targeted integration and expression of exogenous nucleic acid sequences	  	200800610-8	  	26-Jul-06	  	Pending
							
	S49	  	US	  	(2008-0131962)	  	Engineered Cleavage Half-domains	  	11/805,850	  	23-May-07	  	Pending
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	S49	  	PCT	  	WO2007139898	  	Engineered Cleavage Half-domains	  	US07/012411	  	23-May-07	  	National Phase
							
	S49	  	AU	  		  	Engineered Cleavage Half-domains	  	2007267887	  	23-May-07	  	Pending
							
	S49	  	CA	  	(2,651,494)	  	Engineered Cleavage Half-domains	  	2,651,494	  	23-May-07	  	Pending
							
	S49	  	EP	  	(EP2027262)	  	Engineered Cleavage Half-domains	  	7795299.2	  	23-May-07	  	Pending
							
	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]
							
	S52	  	US	  	(20080299580)	  	Targeted integration into the PPP1R12C locus	  	12/150,103	  	24-Apr-08	  	Pending

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 38. 

													
	S52	  	PCT	  	WO2008133938	  	Targeted integration into the PPP1R12C locus	  	 PCT/US2008/
 005282
	  	24-Apr-08	  	Pending
							
	S53	  	US	  	(20080311095)	  	Methods and Compositions for Increased Transgene Expression	  	12/154,439	  	22-May-08	  	Pending
							
	S53	  	PCT	  	WO2008153742	  	Methods and Compositions for Increased Transgene Expression	  	 PCT/US2008/
 006571
	  	22-May-08	  	Pending
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	S55	  	US	  	(20090042250)	  	Methods and Compositions for Inactivating FUT8 expression	  	12/218,035	  	10-Jul-08	  	Pending
							
	S55	  	PCT	  	WO2009009086	  	Methods and Compositions for Inactivating FUT8 expression	  	 PCT/US2008/
 008455
	  	10-Jul-08	  	Pending
							
	S57	  	US	  	(20090111119)	  	Rapid in vivo Identification of Biologically Active Nucleases	  	12/284,887	  	25-Sep-08	  	Pending
							
	S57	  	PCT	  	WO2009042163	  	Rapid in vivo Identification of Biologically Active Nucleases	  	 PCT/US2008/
 011087
	  	25-Sep-08	  	Pending
							
	S58	  	US	  	20090203140	  	Genomic editing in Zebrafish using zinc finger nucleases	  	12/284,897	  	25-Sep-08	  	Pending
							
	S58	  	PCT	  	WO2009042186	  	Genomic editing in Zebrafish using zinc finger nucleases	  	 PCT/US2008/
 011136
	  	25-Sep-08	  	Pending
							
	S59	  	US	  	(20090117617)	  	Methods and Compositions for Targeted Integration	  	12/288,847	  	23-Oct- 08	  	Pending
							
	S59	  	PCT	  	WO2009054985	  	Methods and Compositions for Targeted Integration	  	 PCT/US2008/
 012040
	  	23-Oct-08	  	Pending
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 39. 

													
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	G1	  	US	  	6013453	  	BINDING PROTEINS FOR RECOGNITION OF DNA	  	09/139,762	  	25-Aug-98	  	Issued
							
	G1	  	US	  	RE 39,229	  	BINDING PROTEINS FOR RECOGNITION OF DNA	  	10/033,129	  	27-Dec-01	  	Issued
							
	G1	  	US	  	NP	  	Design of binding proteins for recognition of DNA	  	10/309,578	  	3-Dec-02	  	Pending
							
	G1	  	US	  	NP	  	Relating to binding proteins for recognition of DNA	  	10/397,930	  	25-Mar-03	  	Pending
							
	G1	  	US	  	NP	  	Relating to binding proteins for recognition of DNA	  	10/400,017	  	25-Mar-03	  	Pending
							
	G1	  	US	  	NP	  	Relating to binding proteins for recognition of DNA	  	11/500,162	  	7-Aug-06	  	Pending
							
	G1	  	PCT	  	WO9606166	  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	GB95/01949	  	17-Aug-95	  	National Phase
							
	G1	  	AU	  	698152	  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	32291/95	  	17-Aug-95	  	Issued
							
	G1	  	AU	  	726759	  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	10037/99	  	6-Jan-99	  	Issued
							
	G1	  	CA	  	2,196,419	  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	2,196,419	  	17-Aug-95	  	Issued
							
	G1	  	DE	  	695 35 829.4-08	  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	01 987 037.7	  	17-Aug-95	  	Issued

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 40. 

													
	G1	  	EP	  	EP0781331	  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	95928576.8	  	17-Aug-95	  	Issued
							
	G1	  	EP	  	(EP2022856)	  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	8015286.1	  	17-Aug-95	  	Pending
							
	G1	  	FR	  		  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  		  	17-Aug-95	  	issued
							
	G1	  	GB	  		  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  		  	17-Aug-95	  	issued
							
	G1	  	JP	  	4118327	  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	507857/1996	  	17-Aug-95	  	Issued
							
	G1	  	JP	  		  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  	332964/2007	  	25-Dec-07	  	Pending
							
	G1	  	LU	  		  	IMPROVEMENTS IN OR RELATING TO BINDING PROTEINS FOR RECOGNITION OF DNA	  		  	17-Aug-95	  	Issued
							
	G2	  	US	  	(2007-0009962)	  	NUCLEIC ACID BINDING POLYPEPTIDE LIBRARY	  	11/514,850	  	31-Aug-06	  	Pending
							
	G2	  	US	  	(2007-0009948)	  	NUCLEIC ACID BINDING POLYPEPTIDE LIBRARY	  	11/514,671	  	1-Sep-06	  	Pending
							
	G2	  	PCT	  	WO9853057	  	NUCLEIC ACID BINDING POLYPEPTIDE LIBRARY	  	GB98/0001510	  	26-May-98	  	National Phase
							
	G2	  	AU	  	737756	  	NUCLEIC ACID BINDING POLYPEPTIDE LIBRARY	  	75422/98	  	26-May-98	  	Issued
							
	G2	  	CA	  	2,290,720	  	NUCLEIC ACID BINDING POLYPEPTIDE LIBRARY	  	2,290,720	  	26-May-98	  	Issued
							
	G2	  	EP	  	(EP0983349)	  	NUCLEIC ACID BINDING POLYPEPTIDE LIBRARY	  	98922963.8	  	26-May-98	  	Pending
							
	G2	  	JP	  		  	NUCLEIC ACID BINDING POLYPEPTIDE LIBRARY	  	10-550153	  	26-May-98	  	Pending

  

 41. 

													
	G2	  	JP	  		  	NUCLEIC ACID BINDING POLYPEPTIDE LIBRARY	  	2008-278701	  	29-Oct-08	  	Pending
							
	G3	  	US	  	6746838	  	NUCLEIC ACID BINDING PROTEINS	  	09/424,487	  	26-May-98	  	Issued
							
	G3	  	US	  	7241573	  	NUCLEIC ACID BINDING PROTEINS	  	10/832,735	  	26-Apr-04	  	Issued
							
	G3	  	US	  	(20070077227)	  	NUCLEIC ACID BINDING PROTEINS	  	11/486,962	  	14-Jul-06	  	pending
							
	G3	  	PCT	  	WO9853058	  	NUCLEIC ACID BINDING PROTEINS	  	GB98/01512	  	26-May-98	  	National Phase
							
	G3	  	BE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	issued
							
	G3	  	CA	  	(2,290,717)	  	NUCLEIC ACID BINDING PROTEINS	  	2,290,717	  	26-May-98	  	Pending
							
	G3	  	CH	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	Issued
							
	G3	  	EP	  	EP0983350	  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	Issued
							
	G3	  	EP	  	EP1982998	  	NUCLEIC ACID BINDING PROTEINS	  	8008211.8	  	29-Apr-08	  	Pending
							
	G3	  	FR	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	Issued
							
	G3	  	GB	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	Issued
							
	G3	  	HK	  	(1120814A)	  	NUCLEIC ACID BINDING PROTEINS	  	9100149.1	  		  	Pending
							
	G3	  	IE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	Issued
							
	G3	  	IT	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	Issued
							
	G3	  	NE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	Issued
							
	G3	  	SE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922964.6	  	26-May-98	  	Issued
							
	G4	  	US	  	6866997	  	NUCLEIC ACID BINDING PROTEINS	  	09/424,488	  	26-May-98	  	Issued
							
	G4	  	US	  	7241574	  	NUCLEIC ACID BINDING PROTEINS	  	10/853,437	  	24-May-04	  	Issued
							
	G4	  	US	  	(2007-0161014)	  	NUCLEIC ACID BINDING PROTEINS	  	11/515,369	  	Aug. 31, 2006	  	Pending
							
	G4	  	PCT	  	WO9853060	  	NUCLEIC ACID BINDING PROTEINS	  	GB98/01516	  	26-May-98	  	National Phase
							
	G4	  	AU	  	732017	  	NUCLEIC ACID BINDING PROTEINS	  	75426/98	  	26-May-98	  	Issued
							
	G4	  	BE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G4	  	CA	  	(2,290,886)	  	NUCLEIC ACID BINDING PROTEINS	  	2,290,886	  	26-May-98	  	Pending
							
	G4	  	CH	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G4	  	DE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued

  

 42. 

													
	G4	  	EP	  	EP0983351	  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G4	  	EP	  	EP1975233	  	NUCLEIC ACID BINDING PROTEINS	  	8008212.6	  	29-Apr-08	  	Pending
							
	G4	  	FR	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G4	  	GB	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G4	  	HK	  	(120832A)	  	NUCLEIC ACID BINDING PROTEINS	  	9199150.7	  	26-May-98	  	Pending
							
	G4	  	IE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G4	  	IT	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G4	  	JP	  		  	NUCLEIC ACID BINDING PROTEINS	  	10-550158	  	26-May-98	  	Pending
							
	G4	  	NE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G4	  	SE	  		  	NUCLEIC ACID BINDING PROTEINS	  	98922967.9	  	26-May-98	  	Issued
							
	G5	  	US	  	6977154	  	NUCLEIC ACID BINDING PROTEINS	  	09/646,353	  	17-Mar-99	  	Issued
							
	G5	  	PCT	  	WO9947656	  	NUCLEIC ACID BINDING PROTEINS	  	GB99/00816	  	17-Mar-99	  	National Phase
							
	G5	  	AU	  	751487	  	NUCLEIC ACID BINDING PROTEINS	  	29449/99	  	17-Mar-99	  	Issued
							
	G5	  	CA	  	(2,323,064)	  	NUCLEIC ACID BINDING PROTEINS	  	2,323,064	  	17-Mar-99	  	Pending
							
	G5	  	EP	  	EP1064369	  	NUCLEIC ACID BINDING PROTEINS	  	99910512.5	  	17-Mar-99	  	Issued
							
	G5	  	GB	  		  	NUCLEIC ACID BINDING PROTEINS	  	99910512.5	  	17-Mar-99	  	Issued
							
	G5	  	IE	  		  	NUCLEIC ACID BINDING PROTEINS	  	99910512.5	  	17-Mar-99	  	Issued
							
	G5	  	LU	  		  	NUCLEIC ACID BINDING PROTEINS	  	99910512.5	  	17-Mar-99	  	Issued
							
	G5	  	MC	  		  	NUCLEIC ACID BINDING PROTEINS	  	99910512.5	  	17-Mar-99	  	Issued
							
	G5	  	NZ	  	506987	  	NUCLEIC ACID BINDING PROTEINS	  	506987	  	17-Mar-99	  	Issued
							
	G6	  	US	  	6733970	  	SCREENING SYSTEM FOR ZINC FINGER POLYPEPTIDES FOR A DESIRED BINDING ABILITY	  	09/851,271	  	9-Nov-99	  	Issued
							
	G6	  	PCT	  	WO0027878	  	SCREENING SYSTEM FOR ZINC FINGER POLYPEPTIDES FOR A DESIRED BINDING ABILITY	  	GB99/03730	  	9-Nov-99	  	National Phase
							
	G6	  	AU	  	766572	  	SCREENING SYSTEM FOR ZINC FINGER POLYPEPTIDES FOR A DESIRED BINDING ABILITY	  	10613/00	  	9-Nov-99	  	Issued

  

 43. 

													
	G6	  	NZ	  	511564	  	SCREENING SYSTEM FOR ZINC FINGER POLYPEPTIDES FOR A DESIRED BINDING ABILITY	  	511564	  	9-Nov-99	  	Issued
							
	G7	  	US	  	6706470	  	GENE SWITCHES	  	09/995,973	  	28-Nov-01	  	Issued
							
	G7	  	PCT	  	WO0073434	  	GENE SWITCHES	  	GB00/02071	  	30-May-00	  	National Phase
							
	G8	  	US	  	(20030092010)	  	Molecular Switches	  	09/996,484	  	28-Nov-01	  	Pending
							
	G8	  	PCT	  	WO0100815	  	Molecular Switches	  	GB00/02080	  	30-May-00	  	National Phase
							
	G8	  	AU1	  	778150	  	Molecular Switches	  	50906/00	  	30-May-00	  	Issued
							
	G8	  	AU2	  	2005200548	  	Molecular Switches	  	2005 200548	  	9-Feb-05	  	Issued
							
	G8	  	CA	  	(2,369,855)	  	Molecular Switches	  	2,369,855	  	30-May-00	  	Pending
							
	G11	  	US	  	(2003-0119023)	  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	10/198,677	  	19-Jan-01	  	Pending
							
	G11	  	PCT	  	WO0153480	  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	GB01/00202	  	19-Jan-01	  	National Phase
							
	G11	  	AU	  	2001 226935	  	Nucleic acid binding polypeptides	  	2001 226935	  	19-Jan-01	  	Issued
							
	G11	  	CA	  	(2,398,155)	  	Nucleic acid binding polypeptides	  	2,398,155	  	19-Jan-01	  	Pending
							
	G11	  	EP	  	EP1250424	  	Nucleic acid binding polypeptides	  	01 901 276.4	  	19-Jan-01	  	Issued
							
	G11	  	BE	  		  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	01 901 276.4	  	19-Jan-01	  	Issued
							
	G11	  	CH	  		  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	01 901 276.4	  	19-Jan-01	  	Issued
							
	G11	  	DE	  		  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	01 901 276.4	  	19-Jan-01	  	Issued
							
	G11	  	FR	  		  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	01 901 276.4	  	19-Jan-01	  	Issued
							
	G11	  	GB	  		  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	01 901 276.4	  	19-Jan-01	  	Issued
							
	G11	  	IE	  		  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	01 901 276.4	  	19-Jan-01	  	Issued
							
	G11	  	HK	  	HK1050713	  	Nucleic acid binding polypeptides characterized by Flexible Linkers	  	3102869.1	  	19-Jan-01	  	Issued
							
	G19	  	PCT	  	WO02057308	  	Nucleic acid binding polypeptides	  	GB02/00246	  	22-Jan-02	  	National Phase

  

 44. 

													
	G19	  	US	  	(20040110923)	  	Nucleic acid binding polypeptides	  	10/470,065	  	22-Jan-02	  	Pending
							
	G22	  	PCT	  	WO02079418	  	Gene Regulation II	  	US2002/09703	  	28-Mar-02	  	National Phase
							
	G22	  	US	  	(20050235369)	  	Gene Regulation II	  	10/473,238	  	28-Mar-02	  	Pending
							
	G23	  	PCT	  	WO02099084	  	Composite Binding Polypeptides	  	US2002/22272	  	4-Apr-02	  	National Phase
							
	G23	  	US	  	(2004-0197892)	  	Composite Binding Polypeptides	  	10/474,282	  	4-Apr-02	  	Pending
							
	L3	  	US	  	(2003-0232410)	  	Methods and compositions for using zinc finger endonucleases to enhance homologous recombination	  	10/395,816	  	20-Mar-03	  	Pending
							
	L3	  	US	  	(2008-0209587)	  	METHODS AND COMPOSITIONS FOR USING ZINC FINGER ENDONUCLEASES TO ENHANCE HOMOLOGOUS RECOMBINATION	  	11/975,017	  	17-Oct-07	  	Pending
							
	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]
							
	L3	  	PCT	  	WO0380809	  	METHODS AND COMPOSITIONS FOR USING ZINC FINGER ENDONUCLEASES TO ENHANCE HOMOLOGOUS RECOMBINATION	  	US2003/09081	  	20 Mar-03	  	National Phase
							
	L3	  	AU	  	2003218382	  	METHODS AND COMPOSITIONS FOR USING ZINC FINGER ENDONUCLEASES TO ENHANCE HOMOLOGOUS RECOMBINATION	  	2003 218382	  	20-Mar-03	  	issued
							
	L3	  	AU	  	2007201617	  	METHODS AND COMPOSITIONS FOR USING ZINC FINGER ENDONUCLEASES TO ENHANCE HOMOLOGOUS RECOMBINATION	  	2007 201617	  	20-Mar-03	  	Issued
							
	L3	  	CA	  	(2,479,858)	  	METHODS AND COMPOSITIONS FOR USING ZINC FINGER ENDONUCLEASES TO ENHANCE HOMOLOGOUS RECOMBINATION	  	2,479,858	  	20-Mar-03	  	Pending

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 45. 

													
	L3	  	EP	  	(EP1504092)	  	METHODS AND COMPOSITIONS FOR USING ZINC FINGER ENDONUCLEASES TO ENHANCE HOMOLOGOUS RECOMBINATION	  	03 714 379.9	  	20-Mar-03	  	Pending
							
	D1	  	PCT	  	WO2008021207	  	Zinc Finger Nuclease-mediated homologous recombination	  	US07/17748	  	9-Aug-07	  	Pending
							
	D1	  	AR	  		  	Zinc Finger Nuclease-mediated homologous recombination	  	70103561	  	11-Aug-07	  	Pending
							
	D1	  	AU	  		  	Zinc Finger Nuclease-mediated homologous recombination	  	US07/17748	  	11-Aug-07	  	Pending
							
	D1	  	BR	  		  	Zinc Finger Nuclease-mediated homologous recombination	  	US07/17748	  	11-Aug-07	  	Pending
							
	D1	  	CA	  		  	Zinc Finger Nuclease-mediated homologous recombination	  	US07/17748	  	11-Aug-07	  	Pending
							
	D1	  	CN	  		  	Zinc Finger Nuclease-mediated homologous recombination	  	US07/17748	  		  	Pending
							
	D1	  	EP	  	(EP2049663)	  	Zinc Finger Nuclease-mediated homologous recombination	  	7811226.5	  	9-Aug-07	  	pending
							
	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]
							
	D1	  	IL	  		  	Zinc Finger Nuclease-mediated homologous recombination	  		  		  	Pending
							
	D1	  	IN	  		  	Zinc Finger Nuclease-mediated homologous recombination	  	US07/17748	  	11-Aug-07	  	Pending
							
	D1	  	JP	  		  	Zinc Finger Nuclease-mediated homologous recombination	  		  		  	Pending
							
	D1	  	TW	  		  	Zinc Finger Nuclease-mediated homologous recombination	  	96129695	  	11-Aug-07	  	Pending
							
	D1	  	TH	  		  	Zinc Finger Nuclease-mediated homologous recombination	  	701004008	  	11-Aug-07	  	Pending
							
	[***]	  	[***]	  		  	[***]	  		  		  	[***]
							
	D1	  	UA	  		  	Zinc Finger Nuclease-mediated homologous recombination	  		  		  	Pending
							
	D1	  	ZA	  		  	Zinc Finger Nuclease-mediated homologous recombination	  		  		  	Pending

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 46. 

													
	D2	  	US	  	(2008-0182332)	  	Optimized non-canonical Zinc Finger Proteins	  	12/001,939	  	13-Dec-07	  	Pending
							
	D2	  	PCT	  	WO2008076290	  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	13-Dec-07	  	Pending
							
	D2	  	AR	  		  	Optimized non-canonical Zinc Finger Proteins	  	70105643	  	14-Dec-07	  	Pending
							
	D2	  	AU	  		  	Optimized non-canonical Zinc Finger Proteins	  	2007334468	  	14-Dec-07	  	Pending
							
	D2	  	BR	  		  	Optimized non-canonical Zinc Finger Proteins	  		  		  	Pending
							
	D2	  	CA	  		  	Optimized non-canonical Zinc Finger Proteins	  		  		  	Pending
							
	D2	  	CO	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	CN	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	CR	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	EP	  	(EP2092068)	  	Optimized non-canonical Zinc Finger Proteins	  	07 853 356.9	  	13-Dec-07	  	Pending
							
	D2	  	EG	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	ID	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	IN	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	JP	  		  	Optimized non-canonical Zinc Finger Proteins	  		  		  	Pending
							
	D2	  	KR	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending

  

 47. 

													
							
	D2	  	MX	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	NZ	  		  	Optimized non-canonical Zinc Finger Proteins	  		  		  	Pending
							
	D2	  	PH	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	TH	  		  	Optimized non-canonical Zinc Finger Proteins	  	701006408	  	14-Dec-07	  	Pending
							
	D2	  	TW	  		  	Optimized non-canonical Zinc Finger Proteins	  	96147782	  	14-Dec-07	  	Pending
							
	D2	  	UA	  		  	Optimized non-canonical Zinc Finger Proteins	  		  		  	Pending
							
	D2	  	VN	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending
							
	D2	  	ZA	  		  	Optimized non-canonical Zinc Finger Proteins	  	 PCT/US2007/
 025455
	  	14-Dec-07	  	Pending

 Licensed from Massachusetts Institute of Technology 
  

													
	M1	  	US	  	5789538	  	Zinc finger proteins with high affinity new DNA binding specificities	  	08/850,250	  	18-Apr-97	  	Issued
							
	M2	  	US	  	6410248	  	GENERAL STRATEGY FOR SELECTING HIGH-AFFINITY ZINC FINGER PROTEINS FOR DIVERSE DNA TARGET SITES	  	09/240,179	  	29-Jan-99	  	Issued
							
	M3	  	US	  	6479626	  	POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS	  	09/260,629	  	1-Mar-99	  	Issued
							
	M3	  	US	  	6903185	  	POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS	  	10/146,221	  	13-May-02	  	Issued
							
	M3	  	US	  	7153949	  	NUCLEIC ACID ENCODING POLY-ZINC FINGER PROTEINS WITH IMPROVED LINKERS	  	11/110,594	  	20-Apr-05	  	Issued
							
	M3	  	US	  	7595376	  	Poly zinc finger proteins with improved linkers	  	11/639,363	  	14-Dec-06	  	issued

  

 48. 

													
	M3	  	PCT	  	WO9945132	  	Poly zinc finger proteins with improved linkers	  	US99/04441	  	1-Mar-99	  	National Phase
							
	M3	  	AU	  	746454	  	Poly zinc finger proteins with improved linkers	  	28849/99	  	1-Mar-99	  	Issued
							
	M3	  	CA	  	(2,321,938)	  	Poly zinc finger proteins with improved linkers	  	2,321,938	  	1-Mar-99	  	Pending
							
	M3	  	EP	  	(EP1060261)	  	POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS	  	99909701.7	  	1-Mar-99	  	Pending
							
	M3	  	JP	  	4309051	  	POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS	  	2000-534663	  	1-Mar-99	  	issued
							
	M3	  	JP	  		  	POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS	  	2009-25146	  	5-Feb-09	  	Pending
							
	M4	  	US	  	NP	  	Dimerizing Peptides	  	09/636,243	  	20-Aug-00	  	Pending

  

 49. 

 Licensed from the Scripps Research Institute 
  

													
	T1	  	US	  	6140466	  	Zinc finger protein derivatives and methods therefor	  	08/863,813	  	27-May-07	  	Issued
							
	T1	  	US	  	6790941	  	Zinc finger protein derivatives and methods therefor	  	09/500,700	  	Feb. 9, 2000	  	Issued
							
	T1	  	US	  	6242568	  	Zinc finger protein derivatives and methods therefor	  	08/676,318	  	30-Dec-96	  	Issued
							
	T1	  	PCT	  	WO9519431	  	Zinc finger protein derivatives and methods therefor	  	US95/00829	  	18-Jan-95	  	National Phase
							
	T1	  	PCT	  	WO9854311	  	Zinc finger protein derivatives and methods therefor	  	US98/10801	  	27-May-98	  	National Phase
							
	T1	  	AU	  	704601	  	Zinc finger protein derivatives and methods therefor	  	16865/95	  	18-Jan-95	  	Issued
							
	T1	  	CA	  	(2,181,548)	  	Zinc finger protein derivatives and methods therefor	  	2181548	  	18-Jan-95	  	Pending
							
	T1	  	EP	  	EP0770129	  	Zinc finger protein derivatives and methods therefor	  	95 908 614.1	  	18-Jan-95	  	Issued
							
	T1	  	FR	  		  	Zinc finger protein derivatives and methods therefor	  	95 908 614.1	  	18-Jan-95	  	Issued
							
	T1	  	GB	  		  	Zinc finger protein derivatives and methods therefor	  	95 908 614.1	  	18-Jan-95	  	Issued
							
	T1	  	FI	  		  	Zinc finger protein derivatives and methods therefor	  	95 908 614.1	  	18-Jan-95	  	Pending
							
	T1	  	JP	  	4012243	  	Zinc finger protein derivatives and methods therefor	  	07-519231	  	18-Jan-95	  	Issued
							
	T1	  	NO	  		  	Zinc finger protein derivatives and methods therefor	  	1996 2991	  	18-Jan-95	  	Pending
							
	T1	  	AU	  	2002300619	  	Zinc finger protein derivatives and methods therefor	  	2002 300619	  	27-May-98	  	issued
							
	T1	  	AU	  	(2007201586)	  	Zinc finger protein derivatives and methods therefor	  	2007 201586	  	27-May-98	  	Pending
							
	T1	  	CA	  	(2,291,861)	  	Zinc finger protein derivatives and methods therefor	  	2,291,861	  	27-May-98	  	Pending
							
	T1	  	EP	  	(EP0988377)	  	Zinc finger protein derivatives and methods therefor	  	98 926 088.0	  	27-May-98	  	Pending
							
	T1	  	JP	  		  	Zinc finger protein derivatives and methods therefor	  	11-500870	  		  	Pending

  

 50. 

 Licensed from the Johns Hopkins University 
  

													
	J1	  	US	  	5356802	  	Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease	  	07/862,831	  	3-Apr-92	  	Issued
							
	J1	  	US	  	5436150	  	Functional domains in flavobacterium okeanokoities (FokI) restriction endonuclease	  	08/126,564	  	27-Sep-93	  	Issued
							
	J1	  	US	  	5487994	  	Insertion and deletion mutants of FokI restriction endonuclease	  	08/346,293	  	23-Nov-94	  	Issued
							
	J1	  	PCT	  	WO9418313	  	FUNCTIONAL DOMAINS IN FLAVOBACTERIUM OKEANOKOITES (FOKI) RESTRICTION ENDONUCLEASE	  	US94/01201	  	10-Feb-94	  	National Phase
							
	J1	  	PCT	  	WO9509233	  	FUNCTIONAL DOMAINS IN FLAVOBACTERIUM OKEANOKOITES (FOKI) RESTRICTION ENDONUCLEASE	  	US94/01943	  	23-Aug-94	  	National Phase
							
	J1	  	CA	  	(2,154,581)	  	FUNCTIONAL DOMAINS IN FLAVOBACTERIUM OKEANOKOITES (FOKI) RESTRICTION ENDONUCLEASE	  	2,154,581	  	10-Feb-94	  	Issued
							
	J1	  	EP	  	(EP1340812)	  	FUNCTIONAL DOMAINS IN FLAVOBACTERIUM OKEANOKOITES (FOKI) RESTRICTION ENDONUCLEASE	  	03 010009.3	  	2-Oct-94	  	Pending
							
	J1	  	JP	  		  	FUNCTIONAL DOMAINS IN FLAVOBACTERIUM OKEANOKOITES (FOKI) RESTRICTION ENDONUCLEASE	  	7-510290	  	23-Aug-94	  	Pending
							
	J1	  	JP	  	4081119	  	FUNCTIONAL DOMAINS IN FLAVOBACTERIUM OKEANOKOITES (FOKI) RESTRICTION ENDONUCLEASE	  	2006-143294	  		  	Issued
							
	[***]	  	[***]	  		  	[***]	  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]
							
	J2	  	US	  	 5792640
 (Re-exam case 90/010,240)
	  	General method to clone hybrid restriction endonucleases using lig gene	  	08/575,361	  	20-Dec-95	  	Issued
							
	J3	  	US	  	5916794	  	Methods for inactivating target DNA and for detecting conformational change in a nucleic acid	  	08/647,449	  	7-May-96	  	Issued
							
	J3	  	US	  	 6265196
 (Re-exam case 90/008,526)
	  	Methods for inactivating target DNA and for detecting conformational change in a nucleic acid	  	09/281,792	  	31-Mar-99	  	Issued

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 51. 

 Licensed from California Institute of Technology 
  

													
	C1	  	US	  	(20050026157)	  	Use of Chimeric Nucleases to stimulate gene targeting	  	10/656,531	  	5-Sep-03	  	Pending
							
	C1	  	PCT	  	WO2004037977	  	Use of Chimeric Nucleases to stimulate gene targeting	  	US03/27958	  	5-Sep-03	  	National Phase
							
	C1	  	AU	  		  	Use of Chimeric Nucleases to stimulate gene targeting	  	2003 298574	  	5-Sep-03	  	Pending
							
	C1	  	CA	  	(2,497,913)	  	Use of Chimeric Nucleases to stimulate gene targeting	  	2,497,913	  	5-Sep-03	  	Pending
							
	C1	  	EP	  	(EP 1581610)	  	Use of Chimeric Nucleases to stimulate gene targeting	  	03 796 324.6	  	5-Sep-03	  	Pending
							
	[***]	  	[***]	  		  	[***]	  		  		  	[***]
							
	C1	  	JP	  		  	Use of Chimeric Nucleases to stimulate gene targeting	  	2005-501601	  	5-Sep-03	  	Pending

  
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

  

 52. 

 Licensed from the University of Utah Research Foundation 
  

													
	U1	  	US	  	(20050208489)	  	Targeted chromosome mutagenesis using zinc finger nucleases	  	10/502,565	  	22-Jan-03	  	Pending
							
	U1	  	PCT	  	WO0387341	  	Targeted chromosome mutagenesis using zinc finger nucleases	  	US03/02012	  	22-Jan-03	  	National Phase
							
	U1	  	AU	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	2003 251286	  	22-Jan-03	  	Pending
							
	U1	  	CA	  	(2,474,486)	  	Targeted chromosome mutagenesis using zinc finger nucleases	  	2,474,486	  	22-Jan-03	  	Pending
							
	U1	  	EP	  	EP1476547	  	Targeted chromosome mutagenesis using zinc finger nucleases	  	03 746 527.5	  	22-Jan-03	  	Issued
							
	U1	  	BE	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	03 746 527.5	  	22-Jan-03	  	Issued
							
	U1	  	BR	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	P10307383	  	22-Jan-03	  	Issued
							
	U1	  	CH	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	03 746 527.5	  	22-Jan-03	  	Issued
							
	U1	  	CN	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	3802664.3	  	22-Jan-03	  	Pending
							
	U1	  	DE	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	03 746 527.5	  	22-Jan-03	  	Issued
							
	U1	  	FR	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	03 746 527.5	  	22-Jan-03	  	Issued
							
	U1	  	GB	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	03 746 527.5	  	22-Jan-03	  	Issued
							
	U1	  	IE	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	03 746 527.5	  	22-Jan-03	  	Issued
							
	U1	  	NL	  		  	Targeted chromosome mutagenesis using zinc finger nucleases	  	03 746 527.5	  	22-Jan-03	  	Issued

  

 53.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]